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Chapter 1
INTRODUCTION
AIM AND OUTLINE OF THE STUDY
1.1 AIM OF THE STUDY
A substantial proportion of subjects with clinically euthyroid goitre expose
suppressed serum TSH levels together with normal serum levels of thyroid
hormones. The objective of this study was to explore some clinical consequen-
ces of this socalled "subclinical hyperthyroidism".
1.2 THE CONCEPT OF SUBCLINICAL HYPERTHYROIDISM
By definition thyrotoxicosis appears when the level of thyroid hormones in
target tissues exceeds the individuals demands (Wiersinga and Krenning,
1988). There is a tight feedback between the thyroid gland and the pituitary,
which is illustrated by a close inverse relationship between serum TSH and
serum T4 (Spencer et al., 1990). In overt thyrotoxicosis elevated serum levels
of thyroid hormones are combined with a flat TSH response after stimulation by
TRH (Ormston et al., 1971).
The condition characterized by TRH-resistant suppression of TSH together
with normal serum levels of thyroid hormones is defined as "preclinical" or
"subclinical" thyrotoxicosis (Evered et al., 1974, Gemsenjager et al., 1976,
Gemsenjager et al., 1983). Subclinical thyrotoxicosis may be exogenous as a
consequence of L-thyroxine treatment, or it may arise spontaneously (Ross,
1991b). This endogenous subclinical hyperthyroidism is most common in mul-
tinodular goitre (Tenerz et al., 1990). In this condition varying degrees of
functional autonomy within the thyroid gland have been established by the
absence of suppressibility of the uptake of radioactive iodine after T3 ad-
ministration (Miller and Block, 1970, Smeulers et al., 1977, Wiarda et al.,
1978). Multinodular goitre is functionally a graded condition in which
euthyroidism may slowly progress through a state of autonomy to hyper-
thyroidism (Miller and Block, 1970, Studer et al., 1978, Studer et al., 1985, Elte
et al., 1990, Berghout et al., 1990). This process takes many years (Elte et al.,
1990). The functional state of autonomy in multinodular goitre is thus identical
with "preclinical" or "subclinical" hyperthyroidism (Elte et al., 1982).
In the seventies much confusion has arised from discrepancies between
T3-suppressibility and the results of TRH-testing in subclinical hyper-
thyroidism (Elte, 1977, Smeulers et al., 1977, Emrich and Bahre, 1978). The
wide availability of more sensitive TSH-assays in the beginning of the eighties
have given a new impulse to the outlining and investigation of subclinical
thyrotoxicosis.
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1.3 TSH-ASSAYS
In the eighties the sensitive immunometric assays (IMA's) for TSH have rapidly
replaced the single antibody radio-immuno assays (RIA's) in clinical practice.
The improved sensitivity of these assays largely results from the "sandwich"-
principle, in which two anti-TSH antibodies, usually monoclonal, are employed
(Nicoloff and Spencer, 1990). The first antibody, bound to a solid phase, is
directed at the specific subunit of TSH and selectively extracts TSH. The bound
TSH is further quantified by a labeled antibody. The label employed could
either be a radioactive molecule ( ' ^ i ) , as in the immuno-radiometric assays
(IRMA's), a fluorophor (immuno-fluorometric assay (IFMA)), an enzyme (im-
muno- enzymmometric assay, (IEMA)) or a chemiluminescent molecule (im-
muno-chemiluminometric assay (ICMA)) (Nicoloff and Spencer, 1990,
Hashimoto et al, 1991).
A Nomenclature Committee of the American Thyroid Association has stated
that a minimal requirement for the predicate "sensitive" of a TSH assay should
be that the serum from clinically hyperthyroid patients will give results that are
more than three log SD below the mean value found in serum from normal
subjects (Larsen et al., 1987). Extended criteria for a sensitive TSH assay to be
used as a first line thyroid function test have been proposed by one of the
members of the Committee (Klee and Hay, 1987):
1) A sensitive TSH assay should have less than 1% overlap between the
variation of the lower reference value limit and the assay detection limit.
2) At least 95% of patients with a subnormal TSH response to TRH stimula-
tion should have basal TSH values below the lower normal value limit.
3) At least 95% of patients who have a normal TSH response to TRH
stimulation should have a detectable basal TSH concentration.
4) At least 95% of hyperthyroid subjects should have values below the assay
detection limit.
5) At least 95% of clinical euthyroid subjects should have a detectable basal
TSH concentration.
Further discrimination between the TSH assays has been performed on the
base of the detection limits of the various assays (Wood et al., 1985, Kreutzer
et al., 1986, Wilke and Utley, 1988, Spencer et al., 1990). From this point of
view TSH-RIA's are "first generation" assays. Each new generation of TSH
assays is demarkated from the previous one by a 10-fold increase in functional
sensitivity (Spencer et al., 1990). Up to now 3 generations of TSH assays have
been defined.
In euthyroidism and various thyroid disorders, including thyroid autonomy,
basal TSH values, measured with a sensitive assay, appear to be highly predic-
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tive for the outcome of TRH-tests (Seth et al., 1984, Caldwell et al., 1985, Gow
et al., 1986, Wiersinga et al.,1986, Lind et al., 1988, John et al., 1989, v.
Hamersvelt et al., 1989, Ross et al., 1989a). However, basal TSH may be
misleading in several conditions, like pituitary disease, depression, major non-
thyroidal illness, usage of several medications and in eldery people (Krenning
and Hennemann, 1986, Hennemann et al., 1987, Larsen et al., 1987, Ehrmann
et al., 1989, Bartalena et al., 1990, Nicoloff and Spencer, 1990, Surks et al.,
1990, Szaboles et al., 1990, Ross et al., 1990, Sawin et al., 1991, DeGroot et al.,
1992).
In multinodular goitre a substantial proportion of subjects is detected with
suppressed basal TSH values and normal serum levels of thyroid hormones
(Gibold et al, 1986, Caldwell et al., 1987, Lind et al., 1988, Ross et al., 1989a,
Tenerz et al., 1990) The prevalence of subclinical hyperthyroidism in multi-
nodular goitre, however, is not well established; some reported figures are
rather high, ranging from 15 to 55% (Gemsenjager et al., 1976, Elte et al., 1977,
Emrich and Bahre, 1978, Berghout et al., 1990). These figures, however, are
based on hospital surveillances, which are most probably biased by selection.
The prevalence of subclinical hyperthyroidism in more randomly selected
populations is estimated at about 2%, being higher in eldery than in younger
people (Tenerz et al., 1990, Parle et al., 1991).
1.4 THYROID HORMONES AND BONE METABOLISM
In 1891 a 23 years old women, named Rosalie Gebus, has been described by
Von Recklinghausen with severe decalcification of the bones due to hyper-
thyroidism (Von Recklinghausen, 1891). This is probably the first description
of the association between osteoporosis and hyperthyroidism. In 1937 Snapper
has described 2 patients with only mild hyperthyroidism and severe painful
osteoporosis, which improved after subtotal thyroidectomy (Snapper, 1937).
Histomorphometric studies of bone in hyperthyroidism have revealed in-
creased osteoclastic as well as osteoblastic activity both in cortical and in
trabecular bone (Meunier et al., 1972, Melsen and Mosekilde, 1977, Eriksen et
al., 1985). The mineralization rate in thyrotoxic bone is increased and the lag
time between osteoblastic apposition and osteoid mineralization is decreased,
resulting in a decrease in osteoid seam width (Eriksen et al., 1985). Reconstruc-
tion of the remodeling sequences have revealed a marked shortening of the bone
remodeling cycle and an increased activation frequency of remodeling cycles in
hyperthyroidism (Eriksen, 1986). These data indicate that the coupling of bone
formation and resorption in hyperthyroidism is undisturbed, and that hyper-
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thyroid bone disease is predominantly characterized by increased bone turn-
over. Relative to the osteoclasts the osteoblasts, however, are supposed to be
less active, resulting in a negative balance between bone formation and resorp-
tion (Meunier et al., 1972, Melsen and Mosekilde 1977, Eriksen et al., 1985).
From histomorphometric observations Meunier et al. (1972) have concluded
that the impact of the bony manifestations in hyperthyroidism is related more to
the duration rather than to the severity of the thyrotoxicosis.
The increased bone turnover in hyperthyroidism is associated with an in-
crease in the serum concentration of alkaline phosphatase (Mosekilde et al.,
1978, Cooper et al., 1979, Bijlsma et al., 1983, Hyldstrup et al., 1988, Tibi et
al., 1989) and in the urinary excretion of hydroxyproline (Kivirikko et al., 1965,
Siersbaek-Nielsen et al., 1971, Mosekilde et al., 1978, Hendriks et al., 1979,
Bijlsma et al., 1983). The renal tubular resorption of calcium in hyper-
thyroidism may be decreased (Mosekilde et al., 1977), which, together with an
increased efflux of calcium from bone (Hendriks et al., 1977), may result in
hypercalciuria. Serum PTH levels in hyperthyroidism are often in the low-nor-
mal range, probably as a result of the slight increase in serum calcium due to the
effect of thyroid hormones on calcium resorption from bone (Mosekilde et al.,
1977, Tibi et al., 1989, Ross et al., 1989b). The observed decline in serum 1,25-
dihydroxyvitamin D3 concentrations, with unaltered 25- hydroxyvitamin D3
concentrations, in hyperthyroidism is probably also mediated by feedback
regulation, induced by the slight increase in serum calcium and the suppressed
PTH. (Bouillon et al., 1980, Jastrup et al., 1982, Peerenboom et al., 1984). The
decline in 1,25-dihydroxyvitamin D3 formation results in decreased intestinal
calcium absorption in hyperthyroid patients (Peerenboom et al., 1984). A direct
effect on bone resorption of both T4 and T3 has been documented in vitro by
calcium kinetic studies, histology and hydroxyproline concentrations in cul-
tured fetal rat bones (Mundy et al., 1976). The probability of the existence of a
nuclear thyroid hormonal receptor in osteoblasts in human is supported by its
demonstration in osteoblastlike osteosarcoma cells in vitro (Rizolli et al., 1986,
Sato et al., 1987).
The introduction of reliable methods of noninvasive measurement of bone
density has given a new dimension to the investigation of hyperthyroid bone
disease. Decreased bone density in hyperthyroidism has been documented by
single and dual photon absorptiometry and by dual energy X-ray ab-
sorptiometry (DEXA) both in the peripheral and in the axial skeleton (Fraser,
1971, Linde and Friis, 1979, Kr0lner et al.,1983, Toh et al., 1985, Lee et al.,
1990, Wakasugi et al., 1993). An increased fracture risk in relation to decreased
forearm bone density in hyperthyroidism has been documented already 20 years
ago (Fraser et al., 1971).
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Recently new biochemical parameters of bone turnover have become avail-
able, with greater sensitivity and specificity than the classical parameters like
alkaline phosphatase and hydroxyproline. One of the first of these parameters
was osteocalcin, which is extensively explored in relation to subclinical hyper-
thyroidism in this study.
1.5 OSTEOCALCIN
Osteocalcin is a calcium binding protein that contains three residues of the
vitamin K dependent amino-acid, gamma-carboxyglutamic acid (Price et al.,
1980a, Vermeer, 1990). This protein has been discovered first in chicken bone
(Hauschka et al., 1975) and in bovine bone (Price et al., 1976), followed by its
identification in human bone (Vermeulen et al., 1989). Osteocalcin, also called
bone Gla-protein (BGP), is produced by osteoblasts (Nishimoto et al., 1980,
Kaplan et al., 1985). 1,25-Dihydroxyvitamin D3 is the main stimulator of
osteocalcin production (Beresford et al., 1984, Morrison et al., 1989, Lian et al.,
1989, Markose et al., 1990, Nielsen et al., 1991). Thyroid hormones, however,
also appear to influence osteocalcin metabolism. A direct effect of T3 on
osteocalcin secretion has been documented in vitro (Rizolli et al., 1986). Os-
teocalcin probably plays a major role in the process of intercellular interaction
between osteoblasts and osteoclasts (Glowacki et al., 1991, DeFranco et al
1991).
A bovine radio-immuno assay that cross-reacts with human osteocalcin has
been developed in the late seventies (Price and Nishimoto, 1980). This has been
followed by a radio-immuno assay against a synthetic human osteocalcin frac-
tion (Jiippner et al., 1986), but only recently a monoclonal antibody raised
against human osteocalcin has been developed (Ohta et al., 1991, Kanzaki et al.,
1992). Most of the clinical studies available on osteocalcin up to now are
performed with (polyclonal) radio-immuno assays against bovine osteocalcin.
Serum osteocalcin levels vary with sex and aging (Delmas et al., 1983a,
Epstein et al., 1984, Delmas et al., 1986, Duda et al., 1988, Worsfold et al.,
1988, Ruffie et al., 1989, Vanderschueren et al., 1990, Tarallo et al., 1990,
Orwoll et al., 1990). A diurnal fluctuation of serum osteocalcin in humans, with
maximum levels during the night and lowest levels in the morning, is well
documented (Gundberg et al., 1985, Nielsen et al., 1990a, Pietschmann et al.,
1990, Nielsen et a l , 1992). A seasonal variation in osteocalcin has been
reported in some studies (Thomsen et al., 1989, Nielsen et al., 1990b), but these
data have not been supported by others (Overgaard et al., 1988, Vanderschueren
etal., 1991).
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Serum osteocalcin levels are influenced by several other factors, like vitamin
K status and alcohol-intake (Knapen et al., 1989, Nielsen et al., 1990c). In-
creased serum osteocalcin levels in renal failure are probably due to both
decreased osteocalcin clearence and increased bone turnover (Delmas et al.,
1983b, Farrugia et al., 1991). A considerable discrepancy exists between the
normal reference limits of serum osteocalcin, given by different investigators,
which makes comparison of absolute values of osteocalcin in reported clinical
studies impossible (Delmas et al., 1983a, Epstein et al., 1984, Delmas et al.,
1986, Duda et al., 1988, Worsfold et al., 1988, Ruffie et al. , 1989,
Vanderschueren et al., 1990, Tarallo et al., 1990, Orwoll et al., 1990). This
might partly be due to structural variation in osteocalcin which might influence
the antibody binding and partly to differences in assay-performance (Jlippner et
al., 1986, Knapen et al., 1989, Delmas et al., 1990, Tracy et al., 1990). There-
fore, it has been advocated in an "Assay Standardization Report on osteocalcin"
to express individual values of osteocalcin as a percentage of serum osteocalcin
in an appropriate population of normal individuals (Delmas et al., 1990).
Although basicly a parameter of osteoblastic function, osteocalcin has been
shown to be a good parameter of bone turnover in steady state situations in
which coupling between osteoblastic and osteolastic activity is intact (Delmas
et al., 1990). In hyperthyroidism the serum osteocalcin concentration is corre-
lated both with the serum alkaline phosphatase concentration and the urinary
hydroxyproline-excretion (Garrel et al., 1986, Martinez et al., 1986, Popelier et
al., 1990). This indicates that in this condition the serum osteocalcin concentra-
tion reflects the rate of bone turnover, which is increased in hyperthyroidism
(Lukert et al, 1986, Garrel et al., 1986, Martinez et al., 1986, Popelier et al.,
1990, Lee et al., 1990). The elevated levels of serum osteocalcin in hyper-
thyroidism coincide with reduced bone density (Lee et al., 1990, Wakasugi et
al., 1993).
1.6 THYROID HORMONES AND THE HEART
Thyroid hormones have profound effects on the cardiac function. These effects
are mediated both by direct and indirect mechanisms. Animal studies, some of
which have been summerized by Oppenheimer (1991), have documented the
expression of genes coding for the thyroid hormone receptor in cardiac tissue.
Recently the thyroid hormone receptor has been characterized in a human cell
line (Weinberger et al., 1986).
Thyroid hormones have a chronotrope influence by a direct effect on sinus
node function. This has been demonstrated in vivo by the observation that in
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hyperthyroid patients the resting heart rate remains elevated after complete
autonomie blockade with propranolol plus atropine (Valcavi et al., 1992).
Myocardiac contractility is enhanced under the influence of thyroid hor-
mones (Fitzsimons et al., 1990). Clinically this is reflected by a decreased
isovolumetric contraction time (time between mitral valve closure and aortic
valve opening or beginning of carotid pulse) and a decreased pre-ejection
period (PEP = time between electric activation and aortic valve opening, respec-
tively beginning of carotid pulse) in hyperthyroidism, as has been first
demonstrated by simultaneous recording of carotid pulse, phonocardiogram and
electrocardiogram (ECG) (Amidi et al., 1968, Parisi et al., 1974), and later by
simuitanous recordings of echocardiography and ECG (Lewis et al., 1979,
Friedman et al., 1982, Tseng et al., 1989). These phenomena are unaltered by
P-blockade (Grossman et a l , 1971, Lien and Aanderund, 1982).
The left ventricular ejection time (LVET = time between aortic valve opening
and closure) in hyperthyroidism may be shortened. Because of the opposite
effects of thyroid hormones on PEP and LVET the ratio between PEP and
LVET gives a more pronounced expression of the altered cardie performance in
thyroid disease (Lewis et al., 1979, Tseng et al., 1989). Correction for increased
heart rate of the declined PEP/LVET ratio does not essentially alter the findings
in hyperthyroidisrn (Tseng et al., 1989). PEP/LVET ratios have been shown to
reflect the thyroid functional status over a wide range of thyroid function from
hypothyroidism to hyperthyroidism (Crowley et al., 1977, Tseng et al., 1989,
Price e ta l . , 1991).
Thyroid hormone excess also alters diastolic performance, resulting in a
shortened isovolumetric relaxation time, and an increased velocity of diastolic
filling (Friedman et al., 1982, Mintzetal., 1991).
Part of the altered cardiac performance of thyroid hormone excess may be
due to altered catecholaminergic function as well, but much confusion about the
extend and pathways of this possibility still remains (Levey et al., 1990).
1.7 DESIGN OF THE STUDY
Most of the studies on the pathophysiologic effects of sublinical thyrotoxicosis
have been performed in L-thyroxine treated subjects. The present study deals
with untreated spontaneous (endogenous) subclinical hyperthyroidism. The
investigations are focused on two target organs for thyroid hormones with
different metabolic and functional characteristics, i.e. the bone, in which chang-
ing metabolic influences are expressed slowly and the heart, in which the
functional status can alter very quickly.
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Multinodular goitre was defined as the subject of interest, as in this condition
endogenous subclinical hyperthyroidism may exist for many years. The study
was confined to females, because of sexual differences in bone metabolism and
the predominance of women over men both in the prevalence of multinodular
goitre and in the clinical consequenses of bone loss. The existence of nodularity
in the thyroid was documented by 99nTrc scanning.
Biochemical determinations in serum of parameters of thyroid function and
bone turnover were performed with commercially available assays; detection
limits, intra- and interassay variations were determined in our own laboratory.
The results of these determinations are presented in the following chapters. As
osteocalcin appeared to be temperature sensitive (table 1) handling of bJood
samples was performed under cooled conditions.
Table 1
Osteocalcin values in 2 healthy volunteers under different temperature conditions.
A and B : aliquots between determinations stored
in a refrigerator at - 20°C,
A' and B' : aliquots between determinations stored
at room temperature.
TIME OSTEOCALCIN (u.g/1)
A A' B B '
30 min. 11 10.2 7.8 7.4
60 min.
120 min.
180 min.
360 min.
10.6
10.8
10.7
10.3
9.9
9.4
9.6
8.7
7.7
7.7
7.6
7.4
7.8
6.8
6.9
6.1
In Ckpfer 2 the value of a second generation TSH assay is explored as a first
line thyroid function test in a population with suspected hyperthyroidism.
In C/wp/er 3 the variation with age and body mass of serum osteocalcin and
bone density in 125 healthy females is described. Interdependent correlations
between these parameters and thyroid function parameters were explored by
multiple regression analysis. Bone density was measured in the forearm by
single photon absorptiometry (SPA). This method has been approved by the
combined American and European Consensus Development Conference as a
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reliable method for the measurement of bone density with a good predictive
value for subsequent fractures of all types (Conference Report 1991)
In CAqpter 4 a cross-sectional study is described of age corrected values of
forearm bone density in 23 women with untreated multinodular goitre and
subchnical hyperthyroidism compared with data obtained in 54 euthyroid
women with multinodular goitres.g
? f u f T "* *° "*"'* <* determinations of osteocalcin, corrected for age
and of alkaline phosphatase in these subjects are described '
In C / , ^ 6 data of PEP/LVET ratios and heart rates are described iIn
pp these subjects are described
data of PEP/LVET ratios and heart rates are described in women
^ 7 * ™ * * ^ i iw h I t o ? ^ 7 * ™ * * « ^ goi^ es in comparison with womenwitn euthyroid multinodular goitres.
T ' * ? "* *™"""* yarding ^"« metabolism and
™ * l°ng'tudinal follow-up of 8 subclinical hyperthyroid
In CJap/er 5 the studies described in this thesis are discussed
In CTwpter 9 all studies are summarized.
of this Chapter are listed in Chapter 8.
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Chapter 2
TSH-IRMA AS FIRST-LINE THYROID FUNCTION
TEST IN SUSPECTED HYPERTHYROIDISM
A.//. AfwüWe, /4J. flasr/aa/we, ƒƒ.
Published (in Dutch) in: Ned Tijdschr Geneeskd, 1987; 131: 2364-2368.
Original title: TSH-IRMA als eerste diagnosticum bij vermoeden van
hyperthyreoïdie.
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SUMMARY
The value of the very sensitive immuno-radiometric assay for TSH
(TSH-IRMA) as first-line thyroid function test was evaluated in 36
patients with suspected hyperthyroidism. On the basis of elevated
serum thyroxine concentration and subnormal response of TSH to
200 micrograms intravenous TRH, as measured by radio-immuno
assay (TSH-RIA), 14 patients were classified as having hyper-
thyroidism. The basal TSH-IRMA concentration appears reliably
to predict the response of TSH to TRH. Moreover, discrimination
between normal basal TSH levels in euthyroidism and subnormal
TSH levels in hyperthyroidism is possible with this IRMA.
TSH-IRMA can serve as a satisfying first-line test for suspected
hyperthyroidism. The diagnosis of hyperthyroidism is very unlike-
ly in case of a normal value. A subnormal value indicates
autonomous thyroid function. In that case determination of thyroid
hormone concentration may confirm the diagnosis of hyper-
thyroidism.
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INTRODUCTION
In the past years several new thyroid function tests have become available. The
disadvantages of the free thyroxine index (FTI), as deducted from the total
serum thyroxine (T4) concentration and the triiodothyronine-resine-uptake,
have induced the development of new tests for the determination of serum free
T4 (FT4) concentrations. Except for the rare case of thyroid stimulating hor-
mone (TSH)-producing pituitary tumors, hyperthyroidism is characterized by
suppression of TSH release. The usual radio-immuno assays for determination
of TSH (TSH-RIA's), however, are not sensitive enough to distinguish between
euthyroidism and hyperthyroidism. In contrast, discrimination between eu- and
hyperthyroidism may be possible with the recently developed immuno-
radiometric assays for TSH (TSH-IRMA's) (1).
We investigated the value of the TSH-IRMA in the first-line evaluation of
suspected hyperthyroidism in a setting of an out-patient Clinic.
SUBJECTS AND METHODS
During a 5 months period all subjects refered to the out-patient Clinic were
tested for FTI, FT4, thyrotropin releasing hormone (TRH)-test and TSH-IRMA.
Serum was stored at a temperature of -20°C for determination of T3 when the
initial determinations gave incompatible results.
The total number of subjects was 36 (28 females and 8 males), aging between
16 - 83 years (mean 51 years). Eleven subjects were using drugs (p-blockers, n
= 4; oral contraceptives, n = 3; digoxine, n = 3; tetracyclic antidepressive
medication, n = 2; disopyramide, n = 1; isosorbide-dinitrate, n = 1; a diuretic, n
= 1; hydralazine, n = 1; ranitidine, n = 1; acenocumarol, n = 1; domperidone, n
= 1 and insulin, n = 1). A ^ ™Tc-thyroid scan was performed in all subjects with
suspected (multi)nodular goitre, De Quervain 's subacute thyroiditis, or
thyrotoxicosis without goitre or exophthalmus. Antibodies against thyroid
microsomes and against colloid were determined according to clinical indica-
tions (absense of goitre or diffuse goitre, with or without exophthalmus).
Following this protocol a "classifying" diagnosis of thyroid disease was made
in 22 subjects: multinodular goitre in 12, auto-immune thyroiditis in 6, De
Quervain's subacute thyroiditis in 2, solitary autonomous thyroid nodule in 1
and goitre related to puberty in 1.
Fasting blood samples were taken between 8.00 and 9.00 a.m.. After
centrifugation aliquots of serum were frozen at -20°C. Serum concentrations of
total-T4 were determined by a double antibody-RIA. FTI was calculated from
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total T4 x T3-resine-uptake. The FTI-reference interval (95% ± 2SD), deter-
mined in our own laboratory in 100 healthy adults, was: 14.7 - 52.4. FT4 was
determined by the "SPAC-FT4-fraction test" (Mallinckrodt Diagnostica, refer-
ence values according to the manufacturer 7.7 - 23.2 pmol/1). TSH-RIA was
determined by a double-antibody-RIA-method (Diagnostic Products Corpora-
tion); clinical lower limit: 1.0 mU/1. TRH testing was performed by intravenous
injection of 200 u.g TRH (Roche). Serum concentrations of basal TSH and
values 20 minutes after injection of TRH were determined by RIA. The TSH
response to TRH was considered subnormal when the increase of TSH was less
than 1 mU/l (A TSH-RIA < 1 mU/1) and normal at values of A TSH > 1 mU/1
(1).
TSH-IRMA determinations were performed with a commercialy available
immuno-radiometric assay against human TSH (CIS, France). An analytical
evaluation of this assay has recently been described (2). Although we deter-
mined the detection limit of this assay at 0.07 mU/1 (concentration 0 standard +
2SD), we used a cut-off value of 0.1 mU/1 to avoid overlap between the clinical
lower limit and the detection limit of the assay. The intra-assay-variations at
TSH concentrations of 0.8, 2.1 and 7.4 mU/1 were 7.3%, 3.9% and 2.9%,
respectively (n = 10). The inter-assay-variations at TSH concentrations of 0.4,
2.2 and 10.5 mU/1 were 8.0%, 6.5% and 6.1%, respectively (n = 29).
The diagnosis of hyperthyroidism was confirmed according to the following
criteria: (a) subnormal response of TSH to injection of TRH and (b) FTI > 52.4
and/or FT4 > 23.2 pmol/1. The diagnosis of hyperthyroidism was rejected when
the response of TSH to TRH was normal, or when at a subnormal response of
TSH to TRH both FTI and the serum concentration of FT4 were normal. In the
last situation the serum concentration of total T3 was determined. Because in no
case this resulted in a diagnosis of "T3-thyrotoxicosis", T3-data are not further
considered here. Note that in this strategy the determination of TSH by IRMA
was not used as a criterium for the diagnosis of hyperthyroidism.
According to Bayes theorema the following definitions were made (3):
FT' FT4 TSH-RIA TSH-IRMA
(pmol/1) (mU/1) (mU/1)
positive test result > 52.4 >23.2 < 1.0 <0.1
negative test result < 52.4 <23.2 > 1.0 >0.1
The total number of subjects with positive, respectively negative test results
= S+, respectively S-. The total number of subjects with subnormal, respective-
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ly normal responses of TSH to TRH = T+, respectively T-. The total number of
subjects with, respectively without hyperthyroidism = H+, respectively H-.
The sensitivity (Se) of the different tests for the outcome of the TRH-test was
defined as the probability (P) of a positive test result when there was a subnor-
mal response of TSH to TRH. In formula: Se = P(S+IT+). The specificity (Sp)
of the different tests for the outcome of the TRH-test was defined as the
probability of a negative test result when there was a normal response of TSH
to TRH: Sp = P(S-IT-). Likewise, related to the diagnosis of hyperthyroidism,
sensitivity and specificity were defined as: Se = P(S+IH+) and Sp = P(S-IH-),
respectively. Taking into account the prevalences {Pr) of subjects with subnor-
mal responses of TSH to TRH, respectively existence of hyperthyroidism in the
study group (Pr = T+, resp. H+l total number of subjects), the positive predictive
value (PV+) of a test result was defined as:
The negative predictive value (PV-) was defined as:
The relation between A TSH-RIA and basal TSH-IRMA was calculated by
linear regression analysis, not considering values below the lower limits of the
assays.
RESULTS
TRH test
Seventeen subjects had a subnormal response of TSH to TRH (Pr = 0.47).
Sixteen of them had serum concentrations of TSH-IRMA < 0.1 mU/1, which
implies a sensitivity of TSH-IRMA for the TRH-test of 0.94.
All of the remaining 19 subjects with a normal response of TSH on TRH had
serum concentrations of TSH-IRMA > 0.1 mU/1 (Sp = 1) (table 1). There
appeared to be a good linear correlation between TSH-IRMA and TSH-RIA (y
= 0.13x + 0.13; r = 0.897; P < 0.001;(fig. 1)). As a consequence of the high
sensitivity and specificity of the TSH-IRMA this assay had higher positive and
negative predictive values than the other tests (table 2).
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Table 1
Determinations in serum of the free-thyroxine-index (FTI), free thyroxine (FT4) concentration
and TSH concentration measured by radio-immunoassay (TSH-RIA) and immuno-
radiometricassay (TSH-IRMA) in 36 subjects suspected for hyper-thyroidism.
Subject
SMAHO/TH
A
B
C
D
E
F
G
H
J
K
L
M
N
0
P
Q
R
/Vorma/ n
S
T
U
V
w
X
Y
z
AABB
CC
DD
BE
FF
GG
HH
JJ
KK
LL
sex
m
f
f
m
f
m
f
f
f
m
m
f
f
f
f
f
f
f
m
f
f
f
f
f
f
f
f
f
f
f
f
f
f
m
m
f
age
(years
diagn.*
)
<m«> o/ rs/Z ro 77f// (A
61
41
58
34
52
34
52
78
42
40
68
41
65
43
66
54
16
?o/TS/Vro
79
39
49
24
65
20
50
65
71
17
76
83
22
69
43
63
68
62
27
AN
MG
MG
AI
AI
AI
MG
MG
QUE
AI
MG
MG
MG
QUE
MG
MG
AI
7YW CA TO
MG
NT
MG
NT
MG
NT
NT
N T
NT
PUB
N T
N T
NT
N T
NT
N T
NT
N T
AI
FTI
49
80
42
51
102
87
60
77
58
93
44
27
52
44
55
37
136
28
26
28
42
54
34
25
41
42
42
42
52
21
43
36
45
32
33
25
FT4
(pmol/1)
<7.0mt///j
30.2
31.4
23.9
24.1
68.5
54.4
25.6
40.5
28.2
45.8
26.2
12.4
28.9
21.4
26.9
19.9
74.6
.OmLW)
15.2
12.5
13.9
17.9
22.5
15.2
12.7
18.6
17.0
16.1
20.8
25.1
9.4
19.2
15.2
20.6
16.2
16.7
10.8
TSH-IRMA
(mU/1)
<0.1
<0.1
<0.1
<01
<0 1
<0 1
<0.1
<0.1
<0 1
0.25
<0 1
<0 1
<0 1
<0.'l
2.0
1.8
4.4
3.5
0.9
2.1
0.6
0.7
1.3
1.6
1.8
0.4
2.0
1.0
1.0
2.1
1.0
0.2
0.8
TSH-RIA
(mU/1)
< 1 0
1.2
< 10
1.0
1.1
1 3
<10
< 10
< 1.0
1.0
< 10
1.0
3.4
2.8
6.8
3.6
1.5
2.5
1.7
1 8
• •O
2.5
3.0
1.3
2.3
1.8
1.6
3.4
1.4
1.1
6.8
AN - autonomie nodule, MG = multinodular goitre, AI = auto-immune-
- De Quervam's subacute thyroiditis, PUB = goitre due to puberty NT = no
disease. '
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Figure 1
Relation between the basal serum concentration of TSH-IRMA
and the TSH-RIA response to 200 ng TRH intravaneously
(A TSH-RIA)
Table 2
Predictive values of different hormonal analyses related to the thyrotropin releasing hormone
(TRH)-test.
FTI FT4 TSH-IRMA TSH-RIA
Sensitivity
Specificity
Positive predictive value
Negative predictive value
0.53
0.95
0.89
0.69
0.82
0.95
0.94
0.86
0.94
1
1
0.95
0.65
0.95
0.92
0.75
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Hyperthyroidism
Following the above defined criteria 14 subjects were considered thyrotoxic (Pr
= 0.39). In the 11 subjects using drugs there were no discrepancies between the
different test results. These subjects are not considered separately in the
presented data. In all hyperthyroid subjects serum concentrations of TSH-
IRMA were < 0.1 mU/1. In two subjects showing a basal TSH-IRMA < 0.1 mU/1
combined with a subnormal response of TSH to TRH, the diagnosis of hyper-
thyroidism was rejected because of normal values of both FTI and of FT4. One
of these had De Quervain's subacute thyroiditis (subject 0), the other had a
multinodular goitre (subject Q). In the former subject a serum determination of
FTI, performed in the same laboratory on request of the primary physician, had
revealed an elevated value (64) 3 weeks before.
In none of the subjects showing serum concentrations of TSH-IRMA > 0.1
mU/1 a diagnosis of hyperthyroidism was confirmed. The positive, respectively
negative predictive values of TSH-IRMA and TSH-RIA are depicted in table 3.
Table 3
Predictive values of different thyroid stimulating hormone (TSH)-assays related to the diagnosis
of hyperthyroidism.
TSH-IRMA TSH-RIA
Sensitivity
Specificity
Positive predictive value
Negative predictive value
DISCUSSION
Several groups of investigators have assigned a central role to the TSH-IRMA
in the strategy of thyroid function testing (1,4,5). It should be noted, however,
that the results of the different studies, including this one, are related to the
composition of the patient groups and to the cut-off values of the different tests.
In this study the prevalence of hyperthyroidism was high, because the subjects
were selected for clinical suspicion of hyperthyroidism. The predictive values
of the different tests are dependent on the prevalence of disease. Sensitivity and
specificity are highly determined by the cut-off values of the different tests. In
this study the variation coefficients of the different assays were not considered
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1
0.91
0.88
1
0.64
0.86
0.74
0.63
in the calculations. Recently Klee and Hay have stressed the importance of
differentiating between the detection limit of the assay and the lower limit of
normal values in the evaluation of different TSH-assays (6). For this reason we
defined the cut-off value of TSH-IRMA at 0.1 mU/1 while the detection limit of
the assay was 0.07 mU/1.
Comparison of both TSH-assays reveals that, in contrast to the RIA method,
the TSH-IRMA gives reliable results in the low range, resulting in a much better
positive predictive value for the outcome of the TRH test. Moreover, there was
a significant correlation between basal TSH-IRMA and the response of TSH to
TRH measured by RIA (fig. 1). This finding is in agreement with data emerging
from other studies in which both basal and A TSH have been determined by RIA
or IRMA, respectively (7,8).
The improved sensitivity of the TSH-IRMA in comparison to the TSH-RIA
is also advantageous in the diagnosis of hyperthyroidism. In our study popula-
tion no case of hyperthyroidism was found at TSH levels > 0.1 mU/1. It thus
appears suitable to reject a diagnosis of primary hyperthyroidism on a basal
TSH value determined by this IRMA, which is not possible with the RIA
method (PV-: 1 and 0.63, respectively). To confirm the diagnosis of hyper-
thyroidism, however, further diagnostic tests are needed. This is illustrated by
the finding that a basal TSH value < 0.1 mU/1 more reliably predicts a positive
test outcome of a TRH-test (PV + = 1) than the existence of hyperthyroidism
(PV + = 0.88). In other words a basal TSH < 0.1 mU/1 is highly predictive for
the existence of autonomie thyroid function, as in "subclinical hyper-
thyroidism" in the case of multinodular goitre (patient Q) and in the early
recovering phase of hyperthyroidism in De Quervain's subacute thyroiditis
(patient 0).
For further testing several thyroid hormone-assays are available. Comparison
of FT4 with the FTI revealed that in the group of subjects showing a subnormal
response of TSH to TRH the serum concentration of FT4 was elevated more
often than the FTI (in 14 and 9 subjects, respectively). The diagnosis of
hyperthyroidism thus was confirmed more often on the base of an elevated
value of FT4 than of the FTI. While both FT4 and the FTI were included in the
criteria for confirmation as well as for rejection of the diagnosis of hyper-
thyroidism, it is not possible to calculate predictive values of these determina-
tions for the diagnosis of hyperthyroidism. However, the possibility that FT4
would be falsely elevated more often than FTI, is unlikely, while both tests gave
only once false positive results (subjects DD and W, respectively) in the 19
subjects showing a normal response of TSH to TRH (indicating euthyroidism
by definition). In daily clinical practice we prefer FT4 rather than FTI, because
FT4 determinations are not influenced by variations in the serum concentrations
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of thyroxine-binding globulin and because of the satisfying experiences with
this assay reported by others (9).
In conclusion we agree with others that the sensitive TSH-IRMA is an
important acquisition in the diagnostic arsenal of hyperthyroidism (4-6). It is
important that the lower limit of the normal range can be distinguished from the
detection limit of the assay. For the TSH-assay used by us a discrimination
value of 0.1 mU/1 appears to be valid in clinical practice. When hyperthyroidism
is suspected TSH-IRMA may be used as first-line test. At TSH-IRMA values >
0.1 mU/1 hyperthyroidism is very unlikely. Values of TSH-IRMA < 0.1 mU/1
indicatie autonomie thyroid function. A supplemental thyroid hormone deter-
mination is required to confirm the diagnosis of hyperthyroidism. This strategy
is shown in fig. 2.
Hyperthyroidism?
TSH-IRMA
subnormal
1
FT4
increased
1
1
hyperthyroidism
\
normal
11
"subclinical
hyperthyroidism" or
T3-thyrotoxicosis
(determine T3)
T
Hyperthyroidism unlikely
Figure 2
Diagram for the diagnostic work-up of hyperthyroidism.
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SUMMARY
In a cross-sectional study in 125 healthy females, aged between 21
and 75 years, the influence of age, body weight, body mass index
and 2 seasons in relation to thyroid function on serum osteocalcin
levels were analyzed. Moreover, body weight, body mass index
and serum concentrations of osteocalcin and thyroid function
parameters were analyzed in relation to forearm bone mineral
density.
Serum concentrations of osteocalcin and thyroid function
parameters were not different in the two periods of the year. The
serum concentration of osteocalcin was independently correlated
with ageO)and body mass index(2) (multiple r = 0.39, PO) <
0.0001, P(2) = 0.013). No correlations were found between os-
teocalcin and thyroid function parameters. Inverse correlations
between osteocalcin and both distal and proximal forearm bone
mineral density were determined by age-related variations in these
variables. Forearm bone mineral density was not correlated with
thyroid function parameters.
In conclusion the value of osteocalcin as a parameter of bone
mineral density is questionable since the correlation between os-
teocalcin and forearm bone mineral density appears to be deter-
mined by age-related variations in both variables. Body mass index
appears to be inversely correlated with bone turnover, but not with
forearm bone mineral density. Variation in thyroid function within
the normal range is neither correlated with bone turnover, nor with
forearm bone mineral density.
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INTRODUCTION
In healthy women parameters of bone turnover, like osteocalcin, and bone
mineral density are determined by hormonal influences and by several other
factors, like age, body composition and possibly seasonal variation ( 1 - 1 1 ) . The
influence of thyroid function on these parameters has recently attracted renewed
attention because of possible adverse effects of mild thyroid hormone excess on
bone metabolism (12 - 14). Information about the relations between serum
osteocalcin concentration, bone mineral density and thyroid function in
euthyroidism is nevertheless scanty. Analysis of these relations, however, is
complicated, while thyroid function itself may be interrelated with age, body
weight, body mass index and season (15 -17) . For this reason we performed the
present study in which we investigated these non-hormonal determinants of
osteocalcin and forearm bone mineral density in relation to thyroid function in
125 healthy females. Moreover the value of osteocaicin as a parameter of bone
mineral density was evaluated.
MATERIAL AND METHODS
One hundred and twenty five healthy women (median (range) age 42 (21 - 75)
years) were recruted from the hospital staff and from patients attending the
Internal or the Gynaecologie out-patient Clinic for minor medical problems,
known to have no influence on bone density or thyroid function. There were 78
premenopausal (median (range) age 36 (21-53) years) and 47 postmenopausal
(median (range) age 59 (40-75) years) women. Informed consent was obtained
from every subject and the study was approved by the hospital's ethical com-
mittee. Blood sampling was performed between 08.00 and 10.00 a.m. From
each patient one sample was taken between April and September (summer
period) and one sample between October and March (winter period). The mean
(+SD) interval between the two measurements was 6.8 (±2.1) months. Serum
osteocalcin was determined by a radio-immuno assay using a rabbit antibovine
osteocalcin antibody (CIS, France). The intra- and interassay coefficients of
variation of this assay in the normal range were 1.7% and 6.3%, respectively.
Serum TSH was determined by an immuno-radiometric assay (CIS, France).
The intra- and interassay coefficients of variation of this assay in the normal
range were 3.9% and 6.5%, respectively. Serum free T4 (FT4) was determined
by the SPAC-FT4 fraction test (Byk-Sangtec Diagnostica, Germany). The intra-
and inter-assay coefficients of variation of this assay in the normal range were
6.7% and 7.4%, respectively. Serum total T3 was determined by a double
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antibody radio-immuno assay (Euro/DPC, Great Britain). The intra- and inter-
assay coefficients of variation of this assay in the normal range were 2.5% and
2.7% respectively. Bone mineral density (BMD) was measured in the non-
dominant forearm by single-photon absorptiometrie (Nuclear Data ND1100 A,
U.S.A.). BMD-measurements were expressed in arbitrary units per square
centimeter (U/crn^). The reproducibility of this method was assessed by 5
repeated measurements in 5 healthy volunteers within two weeks, resulting in
coefficients of variation for the distal BMD and for the proximal BMD of 3.1%
and 1.9%, respectively.
Analysis of the data was performed using a statistical computer program
(GB-stat, Dynamic Microsystems, Inc., U.S.A). Correlations were analyzed
with repeated stepwise multiple linear regression analysis, in which the se-
quence of introduction of the variables in the equation was alternated, in order
to detect interdependency of variables. To avoid entering variables that were
highly interrelated, correlations with distal and proximal BMD and with body
weight and body mass index were analyzed separately. Independent correla-
tions between two variables were further described with the best fitting simple
regression analysis. Differences between mean (± SD) or median (range) values
were compared with the unpaired Students t test, or with the Mann Whitney's
U test when appropriate. P < 0.05 was regarded as statistical significant.
RESULTS
Descriptive data
Body weight and body mass index were normaly distributed with mean (± SD)
values of 70.4 ± 13.9 kg and 25.7 ±4.9 (kg/m*), respectively. Serum osteocalcin
and thyroid function parameters were not different in the two periods of the year
during which the samples were collected (table 1). Therefore, the values of the
samples taken in the period that the BMD measurements were done, were used
for the further analyses.
Correlates of osteocalcin
In the stepwise multiple regression analysis osteocalcin appeared to be in-
depently correlated with age and body mass index, the significance of the
correlation with age being much higher than with body mass index (osteocalcin
= 9.774571+0.080023 aged) - 0.12621 body mass index®; multiple r = 0.39;
P<*) < 0.0001, P<2) = 0.013). The relation of osteocalcin with age was further
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Table 1
Serum osteocalcin and thyroid function parameters in S25 healthy females in two seasons
variable summer winter p-¥atac
osteocalcm (ug/1)
TSH {mU/1)
FT4 (pmol/1)
9.712.9
1.45(0.1-3.9)
12.2 +2 . J
10.3 ± 2.6
1.35(0.27-4.9)
12,6 ±1.9
0 J 5
0,28
ÜJ7
Total T3(nmol/i)* 2.1 ±0.4 2.0 + 0.4 0.29
values as mean (+SD) or median (range); * n = 67
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Figure 1
Relation between serum osteocalcin and age in 125 healthy females, (y = 23.86536 -1.080274x
+ 0.024269 ^ - 0.000161 x'; r = 0.39; P = 0.00O2).
substantiated with cubic regression analysis (fig 1). Univariate analysis did not
show any significant correlations between either osteocalcin and weight (r = -
0-15; P = 0.09) or between osteocalcin and TSH (r = - 0.03; P = 0.74),
osteocalcin and FT4 (r = 0.14; P = 0.13) or osteocalcin and total T3 (r = 0.10; P
= 0.31). When distal and proximal BMD respectively where introduced as first
step in the multiple regression equation osteocalcin revealed inverse correla-
tions with both of these variables (r = - 0.23; P = 0.0093 and r = - 0.27; P =
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Table 2
Multiple regression analysis between serum osteocalcin as dependent variable and forearm bone
density, body mass index and age as independent variables in 125 healthy females.
Dependent
variable
Independent
variable
multiple
r-value
P-value
osteocalcin
osteocalcin
distal BMD
body mass index
age
proximal BMD
body mass index
age
0.40
0.41
0.37
0.0131
0.0011
0.22
0.0146
0.003
Table 3
Simple linear regression analysis between forearm bone density, thyroid function parameters,
body mass and age in 125 healthy females.
Dependent
variable
Independent
variable
TSH
FT4
Total T3*
body weight
body mass index
age
r-value
0.15
0.18
-0.04
-0.08
-0.06
0.01
0.07
0.06
-0.08
-0.05
-0.50
-0.54
P-value
0.09
0.04
0.65
0.38
0.56
0.92
0.42
0.49
0.38
0.55
< 0.0001
< 0.0001
distal BMD
proximal BMD
distal BMD
proximal BMD
distal BMD
proximal BMD
distal BMD
proximal BD
distal BMD
proximal BMD
distal BMD
proximal BMD
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0.0022, respectively). The significance of these correlations, however, was lost
when age was introduced as next step in the regression equation (table 2).
Correlates of bone mineral denstiy
Stepwise multiple regression analysis revealed a tendency to a correlation
between distal BMD and TSH and a weak correlation between proximal BMD
and TSH, when these parameters were introduced as first step in the equation
(table 3). The significance of this correlation, however, was lost when age was
introduced as next step in the equation. None of the other variables was
correlated with forearm BMD (table 3). The correlation between forearm BMD
and age was further substantiated with cubic regression analysis (figs. 2 and 3).
2.00
0.00
16 20 28 30 38 40 45 80 55 60 65 70 78 SO
age (years)
Figure 2
Relation between distal BMD and age in 125 healthy females, (y = 0.974144 - 0.002408 x +
0.000227 x* - 0.000004 *';r = 0.59; P < 0.0001).
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Figure 3
Relation between proximal BMD and age in 125 healthy females, (y = 1 506425 - 0 020131x
+ 0.000674 x*- 0.000007 x^; r = 0.65; P < 0.0001J.
DISCUSSION
A seasonal variation in serum osteocalcin levels has recently been described (8),
but this observation is not supported by the present and other studies (9, 18)!
Although absolute values in serum osteocalcin in relation to age have differed
widely between various studies, most of the data have indicated that serum
osteocalcin in women increases around the menopausal age (2 - 6). The present
data show a slight decline in serum osteocalcin in early adult life, reaching a
nadir in the fourth decade, followed by an increase around the age of fifty,
which tends to reach a plateau phase in the following decades. The relative
contribution of menopause to this age-related variation in osteocalcin cannot be
assessed in this cross-sectional study, while age and years since menopause are
closely interrelated.
Osteocalcin is produced by osteoblasts (19,20). The most important impulse
for osteocalcin production is 1,25-dihydroxyvitamin D3, as was shown both in
vitro and in vivo (19, 21, 22). In osteoblastlike osteosarcoma-cells in rats,
however, a direct effect of T3 on osteocalcin release has been documented (23)!
Conflicting data are reported on the correlation between serum osteocalcin and
thyroid function parameters in thyroid disease. Garrel et al. (24) have reported
a positive correlation between serum osteocalcin and serum T3 in subjects with
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hyperthyroidism. In contrast, other studies, both in overt thyroid hormone
excess and in euthyroid and subclinical thyrotoxic goitre have not established a
correlation between serum concentrations of osteocalcin and thyroid hormones
(4,25,26). An inverse correlation between osteocalcin and TSH, however, has
been reported in goitre disease and in subjects taking L-thyroxine medication
(14,26). Comparison of these data, is difficult because of differences in study
populations and selection criteria. In the present study we couid not establish a
correlation between serum osteocalcin and any of the thyroid function
parameters in 125 euthyroid healthy females. Assuming that osteocalcin is a
sensitive marker of bone turnover this implies that there is no indication that
bone turnover is influenced by the level of thyroid function within the euthyroid
range.
Several investigators have studied osteocalcin in relation to BMD (3, 25, 27
- 29). Johansen et al. (28) have shown that the actual serum osteocalcin level is
correlated with future loss of bone. In hyperthyroidism serum osteocalcin has
been reported to correlate negatively with the Z-score of spinal BMD (25).
Several studies, however, have indicated that biochemical parameters, includ-
ing osteocalcin, have a poor predictive value for the actual BMD (3, 28, 29).
Our data are in agreement with this opinion, showing that the correlation
between osteocalcin and BMD in healthy females is determined by age-related
changes in both parameters. The age-related distribution of forearm BMD in the
present study shows a pattern similar to previously reported Dutch studies usi ng
the same method, although the absolute levels may be slightly different (30, 31).
Forearm BMD is reported to correlate inversely with both body weight (32)
and body mass index (33). Recent studies, however, have indicated that body
fat is a more stronger determinant of BMD than these variables (10, 11). In our
study population neither body weight nor body mass index was correlated with
forearm BMD. In contrast, body mass index appeared to be inversely correlated
with bone turnover reflected by the serum osteocalcin level. This is in agree-
ment with data of Ribot et al. (33) showing a negative influence of obesity on
postmenopausal osteocalcin levels. The absence of a correlation between body
mass index and BMD, despite the inverse correlation between body mass index
and osteocalcin, may be declared by the non-weight bearing function of the
forearm.
Thyroid hormone excess may result in decreased bone density as was shown
both in overt and in subclinical thyrotoxicosis (12, 13, 25). Our present data
show that there is no independent correlation between forearm BMD and
thyroid function parameters in euthyroid healthy females, although a tendency
to lower BMD with lower serum TSH levels was observed.
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In summary in our study of 125 healthy females serum osteocalcin concentra-
tion was highly correlated with age, showing a decline in adult life, reaching a
nadir in the fourth decade and than increasing around the menopausal age to
reach a postmenopausal plateau phase. Since the correlation between osteocal-
cin and forearm BMD is determined by age-related variatons in both variables
the value of osteocalcin as a parameter of BMD is questionable. Body mass
index was independently inversely correlated with bone turnover, reflected by
the serum osteocalcin concentration, but not with forearm BMD. We were
unable to show any influence of variation in thyroid function within the normal
range on either bone turnover or forearm BMD.
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SUMMARY
OBJECTIVES: We wished to determine whether women with
multinodular goitre and spontaneous subclinical hyperthyroidism
have decreased bone density.
DESIGN AND SUBJECTS: Bone density was measured at the distal
and proximal forearm. Data were expressed as Z-scores relative to
the mean values out of 125 control subjects matched for age and
menopause. The Z-scores of 23 women with subclinical hyper-
thyroid goitre (TSH < 0.1 mU/1 and normal values of FT4 and total
T3) and of 54 women with euthyroid goitre were compared.
MEASUREMENTS: Bone density was measured by single photon
absorptiometry. TSH was measured by IRMA, FT4 by RIA.
RESULTS: Relative to the euthyroid goitre subjects the mean +
SEM Z-scores of both the distal and proximal forearm density were
lower (- 0.69 ± 0.17 vs - 0.1 ± 0.18, P < 0.05 and - 0.5 ± 0.18 vs
0.07 ± 0.18, P < 0.05, respectively). Median (range) FT4 in the
subclinical hyperthyroid goitre subjects was significantly higher
than in the euthyroid goitre subjects (15.6 (11 - 23.2) pmol/1 vs 11.9
(8.3 - 18.3) pmol/1, P < 0.001), although still within the normal
range. FT4 correlated inversely with Z-scores of both distal and
proximal forearm bone density in the subjects with subclinical
hyperthyroidism (r = - 0.42, P < 0.05 and r = - 0.45, P < 0.05,
respectively), but not in the euthyroid goitre subjects.
CONCLUSION: These findings indicate that women with un-
treated multinodular goitre and subclinical hyperthyroidism have
reduced bone density in the forearm.
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INTRODUCTION
Hyperthyroidism is a well known cause of osteoporosis (Fraser et al., 1971;
Bayley et al., 1980; Lee et al., 1990). Recent studies have shown that long-term
suppressive treatment with L-thyroxine may reduce bone density (Ross et al.,
1987; Paul et al., 1988). These reports suggest that even small increases in
thyroid hormone levels may contribute to loss of bone density. To investigate
the possibility that spontaneous subclinical hyperthyroidism (suppressed TSH
in combination with normal thyroid hormone levels) can interfere with bone
density we measured peripheral bone density in women with untreated multi-
nodular goitre and laboratory tests consistent with subclinical hyperthyroidism.
In accordance with our earlier finding that TSH values < 0.1 mU/1 have a high
predictive value (p.v. = 1) for a flat TSH-response in a TRH-test (Mudde et al.,
1987) we considered TSH values below 0.1 mU/1 as suppressed. The data
obtained from the bone density measurements in the subjects with subclinical
hyperthyroidism related to controls matched for age and menopause were
compared to age and menopause-corrected data obtained from euthyroid sub-
jects with goitres.
SUBJECTS AND METHODS
Subjects
Subjects were selected from adult women under 70 years attending the out-
patient Clinic, meeting the following criteria: multinodular goitre, confirmed by
a 99mxc scan, normal serum free thyroxine (FT4) (7.7 - 23.2 pmol/1) and normal
or suppressed serum TSH (TSH < 3.5 mU/l). If the serum TSH was suppressed
(TSH < 0.1 mU/1) serum triidothyronine was determined to exclude "T3-
thyrotoxicosis".
Excluded were subjects with coexisting disease or treatment known to in-
fluence thyroid or bone metabolism or with a past history of thyroid dysfunc-
tion. Subjects who had been treated with radioactive iodine or by thyroid
surgery were excluded as well.
The ages of all subjects were determined to the nearest month. The subjects
were divided into two groups. Group I consisted of 23 (six pre- and 17 post-
menopausal) subjects with subclinical hyperthyroidism, median age (range)
57.2 (37 - 70.7) years. The post-menopausal subgroup ranged from 1.6 to 23.7
years since the menopause. The mean ± SEM body weight was 67.9 ± 1.8 kg.
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Group II consisted of 54 (29 pre- and 25 post-menopausal) euthyroid
subjects, median age (range) 48.6 (24 - 69.8) years The post
subgroup ranged from 1.5 to 22.5 years since the menopause The
body weight was 71.3 kg ± 1.5 kg.
One hundred and twenty-five female control subjects (78 pre- and 47 post
menopausal between 20 and 75 years were recruited from the hospital s t a S "
from patients with minor medical problems, known to have no influence «
bone density or thyroid function, attending the Internal or the Gynaeco og
ou -patient Clinic. The mean ± SEM body weight of the control group was 0
Methods
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Data from the groups are expressed as mean ± SEM, or median (range) when
not normally distributed. Differences between groups were compared by un-
paired Student's t-test and Wilcoxon's rank sum test when appropriate. Two-
tailed P-values below 0.05 were considered statistically significant. Pearson's
correlation coefficient for linear regression was used to determine the relation-
ship between two variables.
RESULTS
In the total group of subclinical hyperthyroid goitre subjects (group I) the
DBMC/BW vs the DBMC/BW in the age matched controls (n = 95) was 0.78 ±
0.03 vs 0.93 ± 0.02 (P < 0.01). The PBMC/BW in group I vs the PBMC/BW in
the age matched controls (n = 95) was 1.09 ± 0.04 vs 1.22 ± 0.02 (P < 0.01). In
the total group of euthyroid goitre subjects (group II) the DBMC/BW vs the
DBMC/BW in the age matched controls (n = 125) was 0.95 ± 0.02 vs 0.95 +
0.01 (NS). The PBMC/BW in group II vs the PBMC/BW in the age matched
controls (n = 125) was 1.25 ± 0.02 vs 1.24 ± 0.02 (NS).
Individual values of Z-scores of BMCs of the goitre subjects are shown in
Figs. 1 and 2. The Z-scores of both DBMC/BW and PBMC/BW in group I were
significantly lower than in group II as shown in Table 1. No correlations
between Z-scores of BMCs and age were found in either group (data not
shown).
Serum FT4 in group I was significantly higher than in group II as shown in
Table 1. In group I there was an inverse correlation between FT4 and Z-score
of DBMC/BW (r = - 0.42, P < 0.05) and between FT4 and Z-score of
PBMC/BW (r = - 0.45, P < 0.05) (Figs. 3 and 4). In group II and the healthy
controls there was neither correlation between FT4 and BMCs nor between
TSH and BMCs (data not shown).
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Figure 3
Relation of free thyroxine level to distal bone
mineral content to width ratio in subclinical
hyperthyroid goitre subjects (y = 0.67 -
0.08x; r = - 0.42; P < 0.05).
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Figure 4
Relation of free thyroxine level to proximal
bone mineral content to width ratio in sub-
clinical hyperthyroid goitre subjects (y = 1 -
0.09x; r = - 0.45; P < 0.05).
DISCUSSION
The differences in absolute values of BMCs between groups is biased by
differing numbers of subjects at different ages. Transformation of bone mineral
density to Z-scores has proved to be an efficient technique for quantification of
differences in bone density between groups (Parfitt, 1990). As possible dif-
ferences in bone mass due to thyroid dysfunction could be partly mediated by
the influence of thyroid hormones on body mass, we did not match the control
subjects for body weight.
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The mean Z-scores of both DBMC/BW and PBMC/BW in subjects with
goitre and subclinical hyperthyroidism were significantly lower than those in
euthyroid subjects with goitre. Our finding of reduced bone density at the
forearm in women with spontaneous subclinical hyperthyroidism may be com-
pared with recent studies which have shown reduced bone density in subjects
with subclinical hyperthyroidism due to suppressive treatment with thyroid
hormones (Diamond et al., 1991; Kung & Pun, 1991; Paul et al., 1988; Ross et
al., 1987; Stall et al., 1990; Taelman et al., 1990). Some studies however
suggest that this could be caused by overt hyperthyroidism in the past, rather
than by the actual treatment with L-thyroxine (Adlin et al., 1991; Greenspan et
al., 1991). None of our subjects had a history of hyperthyroidism.
Ross and co-workers (1987) reported that the decreased bone density in the
non-dominant radius in premenopausal women treated with excessive doses of
L-thyroxine was related to the duration of treatment, rather than to the L-
thyroxine dose or the resulting serum levels of thyroid hormones. In particular,
in multinodular goitre a long-standing subclinical hyperthyroidism may exist
(Evered et al., 1974; Elte et al., 1990). Our results support the view that the
degree of reduction in bone mass seems to be correlated with the duration rather
than the severity of thyroid hormone excess, as was shown before in hyper-
thyroidism (Meunier et al., 1972).
The median FT4 in the subjects with goitre and subclinical hyperthyroidism,
although still in the normal range, was higher than that in euthyroid subjects
with goitre. This is in accordance with studies that show that subjects with low
TSH and normal T3 and T4 have slightly elevated levels of FT4 when compared
with subjects with TSH within the normal range (Caldwell et al., 1985; 0'-
Mailey et al., 1989). FT4 correlated inversely with the Z-scores of'both
DBMC/BW and PBMC/BW in the patients with goitre and suppressed TSH. A
similar correlation was reported between the free thyroxine index and Z-score
of bone mass of the femoral neck in L-thyroxine treated subjects (Kung & Pun,
1991). In both euthyroid goitre subjects and the control subjects in our study
there was no correlation between FT4 and Z-scores of BMCs or TSH and
Z-scores of BMCs, indicating that in the normal range of TSH different levels
of FT4 have no impact on bone mass at the forearm. Our data indicate that
normal TSH represents euthyroidism at the level of bone and suppressed TSH
represents "tissue thyrotoxicosis" at the level of bone with an increasing effect
on forearm bone density with rising titres of FT4.
In conclusion, women with untreated multinodular goitre and spontaneous
subclinical hyperthyroidism have reduced bone density at both the distal and
proximal forearm in comparison with euthyroid goitre subjects. The reduction
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in bone density correlates with FT4 levels. Our results suggest that antithyroid
treatment in subclinical hyperthyroidism may be beneficial, although the effect
of this treatment on bone density has yet to be established.
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SUMMARY
In 77 consecutively selected women with nontoxic multinodular
goitre 23 subjects had subclinical hyperthyroidism as defined by
suppressed basal serum TSH values (TSH < 0.1 mU/1) in combina-
tion with normal serum thyroid hormone levels. These subjects had
a significantly higher median age and serum FT4 than the remain-
ing 54 euthyroid goitre subjects (57 (37-71) vs 48.5 (24 -69) years;
P = 0.0064, resp. 16.9 (11-23.2) vs 12.3 (8.3-18.3) pmol/1; P =
0.01). Both median (range) serum osteocalcin and serum alkaline
phosphatase were higher in the subclinical hyperthyroid than in the
euthyroid goitre subjects (12.4 (6.7-19.6) vs 9.9 (4.6-18.8) ju.g/1, P
= 0.01, resp. 74 (42-95) vs 55 (29-94) U/l; P = 0.0034). Expression
of osteocalcin values as Z-scores showed that the difference in
osteocalcin was not due to the difference in age between the two
groups. Both in the euthyroid and in the subclinical hyperthyroid
goitre subjects osteocalcin was significantly correlated with
alkaline phosphatase (y = 4.3998 + 0.0997x; r = 0.51; P< 0.001 and
y = 5.4362 + 0.0997x; r = 0.45; P = 0.0313, resp.). These data
indicate that women with subclinical hyperthyroid multinodular
goitre have increased bone turnover, which may indicate a risk for
increased loss of bone.
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INTRODUCTION
In a recent study we have shown that women with subclinical hyperthyroidism
due to multinodular goitre have a decreased forearm bone mineral density (1).
This may be due to increased bone turnover, as has been found in overt
hyperthyroidism (2 - 4). Osteocalcin has been shown to be a useful parameter
of bone turnover in metabolic bone disease (5 - 8). We have previously reported
preliminary results of serum osteocalcin measurements in women with multi-
nodular goitre (9). Here we report extended data concerning osteocalcin and
alkaline phosphatase measurements in women with untreated subclinical hyper-
thyroid multinodular goitres in comparison with data obtained in women with
euthyroid goitres.
SUBJECTS AND METHODS
Details of the patient groups are described elsewhere (1). In short, consecutively
selected women with untreated nontoxic multinodular goitre from the out-
patient Clinics were divided in a group of 23 women with spontaneous subclini-
cal hyperthyroidism (age ranging from 37 - 70 years) and a group of 54
euthyroid women (age ranging from 24 - 70 years) . There were 17
postmenopausal women in the subclinical hyperthyroid group (median (range)
time since menopause 12.5 (1.5 - 24) years). There were 25 postmenopausal
women in the euthyroid group (median (range) time since menopause 8 (1.5 -
23) years). Women with co-existing diseases or taking drugs known to in-
fluence thyroid, bone or liver metabolism were excluded. Subclinical hyper-
thyroidism was defined as suppressed basal serum TSH (TSH < 0.1 mU/1) in
combination with normal serum levels of FT4 and total T3. Serum T3 values
were only determined in women with suppressed TSH to exclude T3-
thyrotoxicosis and are not further considered here. Osteocalcin was determined
in cooled morning sampled serum, using a bovine RIA method (CIS, France).
The intra- and interassay variations in the normal range were 1.7% and 6.3%
respectively. In a study in healthy women we have found a significant correla-
tion between the serum osteocalcin concentration and age (y = 23.8654 -
1.0803x + 0.0243x2.0.0002x3, ^  = Q.39; P = 0.0002) with a mean (± SD) serum
osteocalcin concentration of 10.1 ± 2.9 (i.g/1 (details described in Chapter 3). We
therefore corrected the individual data in the goitre subjects by calculating
Z-scores in comparison with 125 healthy females, matched for age and
menopause (± 2,5 years).
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Total serum alkaline phosphatase was determined by an auto-analyzer (Hitachi
717) using a routine calorimetric method with p-nitrofenyl- phosphate as sub
strata at a temperature of 30T. The reference range of serum alkaline phos-"
S S T r m P ' * " ™\*"™ ™ , determined by a second generation
39% to fw T ^ ' ^ "UT*** *"* ****** ™**™ ™ ^ from3.9 /, to 10% in the normal and low range of TSH, respectively. Serum FT4 was
determined by the "SPAC-FT4-fraction test" (Byk - Sangtec Diagnostica, Ge"
many). The intra- and interassay variation in the normal range (7 7 - 23 2
pmol/1) were 6.7% and 8.7%, respectively.
Data are expressed as median (range), unless otherwise stated. Differences
between groups were compared with Mann - Whitney's U test P < 0 05 was
S ^ W ^ ^ H " * * ^ " * " * " ' • —^—efficient for linear
was used to determine the relationship between two variables.
RESULTS
hyperthyroidism were significantly older than the
, although all values were within the normal range (table 1) Both median
(table 1). When the osteocalcin data were '"orrec^rL^ageTnd
age (years)
TSH (mU/1)
FT4 (pmol/1)
osteocalcin (ug/1)
alkaline phosphatase (U/L)
57(37-71)
<0.1
16.9(11-23.2)
12.4(6.7-19.6)
74 (42-95)
EG
(n = 54)
48.5 (24-69)
1.0(0.1-2.7)
12.3(8.3-18.3)
9.9(4.6-18.8)
55 (29-94)
P
0.006
<0.0001
0.01
0.0034
menopause the difference was significant as well (Z-score osteocalcin in sub-
clinical hyperthyroid versus euthyroid women 0.33 (- 1.57 to 3.83) vs - 0.16 (-
2.84 to 3.13) P = 0.0225) (fig. 1).
Both in the euthyroid and in the subclinical hyperthyroid subjects there was
a significant correlation between serum osteocalcin and serum alkaline phos-
phatase (figs. 2 and 3). No correlations were found between either osteocalcin
or alkaline phosphatase and thyroid function parameters (data not shown).
When the data of both groups, however, were combined significant correlations
between both the serum osteocalcin concentration and FT4 (y = 6.38 + 0.32x, r
= 0.36; P = 0.0015), and between the Z-score of osteocalcin and FT4 (y = - 1.81
+ 0.14x, r = 0.36; P = 0.0013) were observed.
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Figure 1
Box-plot (Median, 10th, 25th, 75th and 90th percen-
tile) of the Z-scores of osteocalcin values in women
with euthyroid goitre (EG) and subclinical hyper-
thyroid goitre (SHG).
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100
Alkaline phosphatase, U/l
Figure 2
Correlation between serum osteocaicin and serum
alkaline phosphatase in 54 women with euthyroid
multinodular goitre (y=4.3998+0.0997x; r=0 51-
P<0.00l).
100
Alkaline phosphatase, U/l
Figure 3
Correlation between serum osteocaicin and serum
alkaline phosphatase in 23 women with subclinical
hyperthyroid multinodular goitre (y = 5 4362 +
0.0997x; r = 0.45; P = 0.0313).
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DISCUSSION
In overt hyperthyroidism bone turnover may be increased, which is biochemi-
cally indicated by increased levels of serum alkaline phosphatase, osteocalcin
and urinary excretion of hydroxyproline and pyridinium cross-links (10 - 16).
Histomorphometric studies have revealed that the major abnormality in hyper-
thyroid bone is an increased bone turnover rate. There are no signs of uncou-
pling between osteoblastic and osteoclastic activity (2 - 4). Although basicly
reflecting bone formation, osteocalcin may be regarded as a parameter of bone
turnover if coupling between osteoblasts and osteoclasts is intact (7, 8).
Most of the information available about bone turnover in subclinical
thyrotoxicosis is derived from L-thyroxine treated subjects. In some studies a
slight increase in mean serum alkaline phosphatase in subclinical thyrotoxic
subjects in comparison with age matched controls has been observed (17, 18).
Individual values in these subjects, however, are mostly within the normal
range (17, 18). Serum osteocalcin also has found to be elevated in subjects
treated with suppressive L-thyroxine doses (17, 18). These data are at variance
with other studies in which no increase in alkaline phosphatase or osteocalcin
in exogenous subclinical thyrotoxicosis has been observed (16, 19 - 21). The
discrepant results could possibly be explained by different matching proce-
dures, or by variance in the extend of thyroid hormone excess. In some of these
studies trends to increased osteocalcin values in L-thyroxine treated subclinical
thyrotoxic subjects could possibly have reached significance if the rather small
study groups would have been extended (16, 20).
In the present study untreated women with endogenous subclinical hyper-
thyroidism due to multinodular goitre had higher median values than euthyroid
controls of both serum alkaline phosphatase and osteocalcin. The individual
values of alkaline phosphatase, however, were all within the normal range.
Because of age-and assay-related variations in normal osteocalcin values it has
recently been advocated to express data of osteocalcin as a percentage of
reference values in an appropriate population of normal individuals (22).
Eliminating a possible bias by age-related differences in standard deviation of
normal osteocalcin values we prefered, according to Duda et al. (23), to express
the osteocalcin data as Z-scores rather than as percentages. Correction of the
data in this way showed that there was still a difference in median osteocalcin
between the subclinical hyperthyroid and euthyroid goitre subjects, which could
therefore not be due to the difference in age between the two groups. Our
findings are in agreement with those of Faber et al.(24) who have reported
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increased levels of both absolute and relative (as a percentage of age matched
controls) osteocalcin values in spontaneous subclinical hyperthyroidism and
confirm our pilot study (9).
In our preliminary data we have found a correlation between the serum
osteocalcin and FT4 concentrations, when the data of euthyroid and subclinical
hyperthyroid goitre subjects were grouped together (9). In the present study this
relation was confirmed, but we could not find a correlation between osteocalcin
and any of the thyroid function parameters in the separate groups. This is in
agreement with most other studies in both overt and subclinical thyrotoxicosis
(13, 15, 17, 18).In the healthy population serum osteocalcin and alkaline phos-
phatase are well correlated (25). The correlation between serum osteocalcin and
alkaline phosphatase in the euthyroid goitre subjects in the present study is in
agreement with these data. In some metabolic bone diseases, a discrepancy
between serum osteocalcin and alkaline phosphatase may exist (5,23). As total
alkaline phosphatase may partly reflect an increased liver fraction in thyroid
hormone excess (10,12), osteocalcin may more accurately reflect the increased
bone metabolism in this condition. Data in overt hyperthyroidism, however,
indicate that in this condition no dissociation between these two parameters
exists (14, 23 - 26). Our data show that in endogenous subclinical hyper-
thyroidism serum osteocalcin and alkaline phosphatase are correlated as well.
Biochemical parameters of bone metabolism, including osteocalcin, do not
correlate very well with actual bone density (Chapter 3,27,28). High osteocal-
cin values, however, may indicate future bone loss (29). Since subclinical
hyperthyroidism in multinodular goitre may exist for many years (30) our data
of increased osteocalcin values in women with subclinical hyperthyroid multi-
nodular goitre may indicate that these subjects are at risk for increased bone
loss. This is in agreement with the decreased forearm bone density, which we
have previously documented in this group of subjects (1).
In conclusion the results of thyroid function tests in women with endogenous
subclinical hyperthyroidism due to multinodular goitre are suggestive for
thyroid hormone excess as indicated by suppressed basal serum TSH levels and
a slightly elevated median serum FT4 concentration in comparison with
euthyroid goitre subjects. Our data indicate that these subjects have increased
bone turnover in comparison with euthyroid goitre subjects, which may indicate
a risk for increased loss of bone.
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Chapter 6
SYSTOLIC TIME INTERVALS AND HEART RATE IN
WOMEN WITH UNTREATED MULTINODULAR
GOITRE
, //. Drosf, A.C. M
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SUMMARY
BACKGROUND: Overt hyperthyroidism has a profound effect on
the cardiovascular system. More recently altered cardiac perfor-
mance in subclinical thyrotoxicosis due to L-thyroxine treatment
has been recognized. Cardiodynamic performance in endogenous
subclinical hyperthyroidism is less well known. This study ob-
jected to determine the cardiac effects in this condition.
DESIGN: In a cross-sectional study systolic time intervals and
heart rates in 27 women with untreated subclinical hyper-
thyroidism associated with multinodular goitre were compared to
data obtained in 27 women with euthyroid multinodular goitres.
METHODS: Resting heart rates and systolic time intervals were
defined as parameters of the cardiac function. Systolic time inter-
vals, expressed as the ratio of the pre-ejection period (PEP) to the
left ventricular ejection time (LVET), were obtained from simul-
taneous electrocardiographic and M-Mode echocardiographic trac-
ings. TSH was measured by IRMA, thyroid hormones by RIA.
RESULTS: Median (range) FT4 in the subclinical hyperthyroid
goitre subjects was higher than in the euthyroid goitre subjects
(16.3 (10 - 23) pmol/1 vs 12.2 (9.3 - 18.3) pmol/1, P = 0.0002),
although individual values were all within the reference range.
Mean (± SD) heart rate in the subclinical hyperthyroid goitre
subjects was significantly higher than in the euthyroid goitre sub-
jects (89,7 ± 12.9 beats/ min vs 80.0 ± 14.4 beats/ min; P = 0.0121).
There was no difference between the mean (+SD) PEP/LVET ratio
in the subclinical hyperthyroid and euthyroid subjects (0.266 ±
0.049 vs 0.281 ± 0.048, P = 0.25).
CONCLUSIONS: In endogenous subclinical hyperthyroidism due
to multinodular goitre resting heart rate is increased, without chan-
ges in PEP/LVET ratios.
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INTRODUCTION
Overt hyperthyroidism has a profound effect on the cardiovascular system (1).
Assessment of systolic time intervals, expressed as the ratio of the pre-ejection
period (PEP) to the left ventricular ejection time (LVET), has proven its validity
as an index of thyroid function (2 - 5). In overt hyperthyroidism PEP is
shortened, while LVET is either unchanged or prolonged, resulting in a
decreased ratio of PEP/LVET (2,3,5 - 7). More recently decreased PEP/LVET
ratios have also been described both in subjects treated with excessive doses of
L-thyroxine and in those with borderline thyrotoxicosis during antithyroid
treatment of hyperthyroidism (5, 8 - 11). These reports refer to altered car-
diodynamic function in subclinical thyrotoxic subjects under treated conditions.
Data on cardiodynamic performance in endogenous subclinical hyper-
thyroidism, however, are scanty. We therefore conducted a cross-sectional
study comparing PEP/LVET ratios and heart rates in women with untreated
subclinical hyperthyroidism associated with multinodular goitre to data ob-
tained in euthyroid women with multinodular goitres.
SUBJECTS AND METHODS
In a pilot study in 20 healthy females we have found a mean PEP/LVET ratio of
0.287 (range 0.233 - 0.317). From this range and an expected difference in the
PEP/LVET ratio of 0.035 (5,9) we estimated that a sample size of 27 subjects
in each group would be required for our study ( a error = 0.05, (i error = 0.20).
The study subjects and controls were consecutively recruted from women
attending the out-patient Clinic because of analysis of nodular goitre. The study
group consisted of 27 women, aged between 28 and 75 years, with untreated
multinodular goitre and subclinical hyperthyroidism. The control group con-
sisted of 27 women, aged between 29 and 65 years, with untreated euthyroid
multinodular goitre. Informed consent of the subjects and approval by the
hospitals ethical committee were obtained. The existence of multinodular goitre
was substantiated by ^ T c scanning. Subclinical hyperthyroidism was defined
as suppressed serum TSH levels (TSH < 0.1 mU/1), in combination with normal
(7.7 - 23.2 pmol/1) serum free T4 (FT4) and normal ( 1 . 5 - 3 . 5 nmol/1) total T3
values, according to the previously observed very high predictive value of the
basal TSH-value for the outcome of the TRH-test (12). Total T3 was only
determined when TSH was below 0.1 mU/1 to exclude "T3-thyrotoxicosis".
Subjects who had been treated for their thyroid disease, or with known cardiac
disease (including disturbance in cardiac rhythm and the use of cardiovascular
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drugs) were excluded from the study.TSH was determined by an immuno-
radiometric assay (CIS, France). The intra-assay variations at TSH concentra-
tions of 0.8 and 2.1 mU/1 were 7.3% and 3.9%, respectively. Inter-assay
variations at TSH concentrations of 0.4 and 2.2 mU/1 were 8.0% and 6.5%
respectively. The detection limit of the TSH-assay was 0.02 mU/1. Serum FT4
was determined by the SPAC-FT4 fraction test (Byk-Sangtec Diagnostica,
Germany). The intra- and inter-assay variations in the normal range (7.7 - 23.2
pmol/1) were 6.7% and 7.4%, respectively. Serum total T3 was determined by a
radio-immunoassay method (Euro/DPC, Great Britain). The intra- and inter-
assay variation in the normal range (1.5 - 3.5 nmol/1) were 2,5% and 2,7%,
respectively.
Systolic time intervals were measured, under stable temperature conditions
with subjects in supine position after a 15 minutes period of rest, from simul-
taneous electrocardiographic and M-mode echocardiographic tracings obtained
from a two-dimensional echocardiogram (Toshiba, SSH-160A) at a paper trac-
ing speed of 100 mm/sec. PEP was the period from the initiation of the q-wave
on the simultaneous ECG-tracing to aortic valve opening. LVET was the time
between aortic valve opening and closure. All PEP/LVET results represent the
mean values obtained from systolic time interval measurements in 3 cardiac
cycles. Corrections for variations in heart rate were calculated according to
Weissler's equation (13) to obtain PEPc/LVETc. Resting heart rates were
recorded during these investigations. All cardiac measurements were performed
by one of us (HD) without knowledge of the subjects thyroid function. The
intra-observer variation of this method was 2.13%.
Differences between groups were tested with unpaired Student's t test or
Mann Whitney's U test when appropriate. Correlations were analysed with
Pearson's linear regression analysis. P-values below 0.05 were considered
statistically significant.
RESULTS
Data on the thyroid function parameters are summarized in table 1. Median FT4
in the subclinical hyperthyroid subjects was significantly higher than in the
euthyroid subjects, although all individual values were within the normal range
(table 1). The subclinical hyperthyroid subjects had a significantly higher mean
resting heart rate than the euthyroid controls (table 2). No significant difference
was found between either mean PEP/LVET ratios or mean PEPc/LVETc ratios
in the two groups (table 2). Individual values of PEP/LVET ratios and heart rate
are depicted in figure 1. There was no significant correlation between thyroid
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80.0 ±14.4
0.281 ±0.048
0.271 ±0.032
89.7 ± 1 2 . 9
0.266 ± 0.049
0.259 ± 0.032
0.0121
0.25
0.22
Table I
Thyroid function parameters in 27 subjects with euthyroid goitre (EG) and in 27 subjects with
subclinical hyperthyroid goitre (SHG).
VARIABLE EG SHG P
TSH(mU/l) 0.76(0.1-2.5) <0.1
Total T3 (nmol/1) 2.6(1.9-3.5)
FT4(pmol/l) 12.2(9.3-18.3) 16.3(10-23.0) 0.0002
Data are expressed as median (range) values.
Table 2
Cardiac performance in 27 subjects with euthyroid goitre (EG) and in 27 subjects with
subclinical hyperthyroid goitre (SHG).
VARIABLE EG SHG P
Heart rate(beats/min)
PEP/LVET ratio
PEPc/LVETc ratio
Data are expressed as means (± SD).
function parameters and systolic time intervals or heart rate, either in the study
group or in the controls, although a non-significant tendency to higher heart
rates at increasing serum FT4 values was documented in the subclinical hyper-
thyroid subjects (r = 0.37, P = 0.06).
DISCUSSION
Systolic time intervals are reported to follow changes in thyroid function
closely (4,8,11). Institution of thyroid replacement therapy in hypothyroidism
is followed by a decrease in PEP and an increase in LVET (4). Overtreatment
of hypothyroid patients with L-thyroxine is common as indicated by slightly
elevated thyroid hormone levels and suppressed TSH in many patients sub-
stituted with thyroid hormones (5, 10, 14, 15). In this medically induced
borderline thyrotoxicosis significantly decreased PEP/LVET ratios are
described (5, 9, 10). Even subjects treated with L-thyroxine who combine
suppressed TSH levels with normal thyroid hormone levels may have shortened
Figure 1
Individual data of PEP/LVET and heart rate in subjects with euthyroid goitre (EG) and in
subjects with subctinicai hyper-thyroid goitre (SHG). * p = 0.0121
systolic time intervals (5). In our study of untreated women with multinodular
goitre, however, we could not detect a significant difference in mean
PEP/LVET ratio between subclinical hyperthyroid and euthyroid women, al-
though there was a tendency to lower values in the former. Corrections for heart
rate did not influence these results significantly. A possible explanation for the
discrepancy between our results and those reported in subjects treated with
L-thyroxine could be found in the consequences of the tightly individually
tuned thyroid-pituitary feedback. Normally individual serum FT4 is restricted
constantly within a narrow range, which is much smaller than indicated by the
reference range for FT4 in the normal population. There seems to be an unique
individual TSH setpoint relative to FT4 levels (16). Once FT4 exceeds the
upper individual limit TSH becomes suppressed. Endogenous subclinical hy-
perthyroidism is a graded condition (17). The small difference in mean FT4
between the subclinical hyperthyroid subjects and the control subjects in our
study suggests that a substantial proportion of the study group was in the very
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early stage of subclinicai hyperthyroidism. Possibly the change in thyroid
function in these subjects was more subtle than in those treated with L-
thyroxine, as reported in the studies mentioned before (5 ,9 , 10).
In contrast to the lack of a significant difference in mean PEP/LVET ratio
between the two groups, mean heart rate was significantly higher in the subjects
with subclinicai hyperthyroidism than in the euthyroid goitre subjects. Absolute
values of heart rate were rather high, with frank sinus tachycardia occurring in
both groups, suggesting psychological stress during the investigations. It seems
unlikely, however, that this would have biased the results, because both groups
were tested under the same conditions. Bell et al. (18) have previously described
that L-thyroxine induced subclinicai thyrotoxicosis affects heart rate more
during sleep than at day-time. Boutin et al. (19) have found mean heart rate in
endogenous subclinicai hyperthyroid subjects half-way between that in
euthyroid and hyperthyroid controls. Dosis reduction of L-thyroxine replace-
ment therapy to the extent of which TSH irresponsiveness to TRH is restored,
is accompanied by a fall in heart rate (15). It is likely that the increase in heart
rate due to the slight thyroid hormone excess in endogenous subclinicai hyper-
thyroidism is mediated by both direct and indirect effects. One of the earliest
cardiovascular effects of thyrotoxicosis is a decrease in peripheral resistance.
By reflex this could induce a cathecholamine mediated increase in cardiac
output (1, 20). On the other hand, thyroid hormones directly increase the
intrinsic activity of the sinus node (21).
In a recent study it has been shown that the severity of thyrotoxic symptoms
does not correlate with thyroid hormone levels in overt hyperthyroidism, at least
in Graves disease (22). In our study in multinodular goitre the increase in heart
rate tended to parallel the serum FT4 levels in the subjects with subclinicai
hyperthyroidism, but the correlation between these parameters reached no
statistical significance.
Suppression of the thyroid-pituitary axis may influence other organ systems
as well as the cardiovascular system. In particular decreased bone density has
been reported in subjects treated with suppressive doses of L-thyroxine (23,24).
We have recently described that also in women with untreated endogenous
subclinicai hyperthyroidism bone density is reduced (25). This, and the findings
in the present study indicate that subjects with spontaneous suppressed TSH
may have subtle symptoms of hyperthyroidism, although serum thyroid hor-
mone levels are within the normal range. Moreover, these subjects seem to be
at risk for developing atrial fibrilliation (26, 27). The cumulating evidence that
subclinicai hyperthyroidism may have harmful effects on target tissues advo-
cates for thyrostatic treatment of this condition. The benificial effect of such a
treatment, however, remains to be established.
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Chapter 7
BONE METABOLISM DURING THYROSTATIC
TREATMENT OF SUBCLINICAL
HYPERTHYROIDISM.
A PRELIMINARY REPORT
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INTRODUCTION
Several reports have indicated that in subclinical thyrotoxicosis due to L-
thyroxine treatment bone turnover is increased and bone density is decreased
(1,2). Endogenous subclinical hyperthyroidism may also have adverse effects
on bone (3,4). It is not clear, however, whether the changes in bone metabolism
are reversible if euthyroidism is restored. To evaluate this possibility we treated
8 subjects with endogenous subclinical hyperthyroid multinodular goitre for a
period up to 24 months and followed bone turnover parameters and bone
density measurements. To avoid the bias of menopause on parameters of bone
metabolism only postmenopausal women were included for treatment, con-
sidering that this cathegory of subjects is at particular risk for developing
osteoporosis. For comparison 8 untreated postmenopausal women with sub-
clinical hyperthyroidism were followed as well. In this Chapter perliminary
results of this still ongoing study are presented.
SUBJECTS AND METHODS
Sixteen postmenopausal women with subclinical hyperthyroid multinodular
goitre were selected for this study. Subclinical hyperthyroidism was defined as
a suppressed serum TSH concentration (TSH < 0.1 mU/1) and FT4 and total T3
concentrations within the reference range. Eight out of these 16 subjects were
randomly assigned to receive thyrostatic treatment. All subjects gave written
informed consent and the study protocol was approved by the hospital's Ethical
Committee. Treatment consisted of methimazole at a starting dose of 10 mg
three times daily. The dose was initially adjusted 6 and 12 weeks after the onset
of treatment and at 3 months intervals thereafter to reach a serum TSH level
between 1 and 3.5 mU/1. The 8 untreated women were followed at 3 months
intervals. The follow-up period was 24 months. In the treatment group follow-
up was incomplete in 3 subjects at 9, 15 and 21 months, respectively. In the
control group follow-up was incomplete in 2 subjects at 24 months. There were
no significant differences between the treatment and the control group. Details
about the subjects are summarized in table 1.
Intra- and interassay variations of serum TSH, determined by a "second
generation" immuno-radiometric assay (International CIS, France), ranged
from 3.9 to 10.0% in the normal and low (TSH < 0.1 mU/1) range, respectively.
Serum FT4, determined by the "SPAC-FT4-fraction test" (Byk-Sangtec Diag-
nostica, Germany), had intra- and inter-assay variations in the normal range (7.7
- 23.2 pmol/1) of 6.7% and 8.7%, respectively. Serum total T3, determined by a
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Table 1
Clinical characteristics of 16 postmenopausal women with subclinicai hypeithyrosd mufs-
nodular goitre. Eight of these were treated with methimazole to reach euthyroidism.
Age, years
FT4, pmol/1
T3, nmol/1
osteocalcin, (j.g/1
alkaline phosphatase, U/l
urinary excretion of
- hydroxyproline/creatinine, umol/mmol
- calcium/creatinine, mmol/mmol
bone density, U/cm
- distal
- proximal
Treatment group
(n = 8)
61.6 ±2 .7
16.7 ±0.4
2.6 ± 0.2
13.2 ± 1.1
72 ±5
22.8 ± 2.4
0.58+0.04
0.74 ± 0.04
1.05 ±0.04
Control group
(n = 8)
62.6 ±2.4
14.8 ±1.2
2.7 ±0.1
13.6 ±0.7
80±4
20.4 ± 2.4
0.49 ± 0.07
0.73 ±0.08
0.99 ±0.10
Data are expressed as mean values ± SEM.
double antibody radio-immuno assay (Euro/DPC. Great Britain), had intra- and
inter-assay variations in the normal range (1.5 - 3.5 nmol/1) of 2.5% and 2.7%,
respectively. Intra- and inter-assay variations of serum osteocalcin, determined
by a bovine radio-immuno assay (International CIS, France), ranged from 1.7%
to 6.7%,in the normal range (3.5 -16.2 ug/1). Total serum alkaline phosphatase
was determined by an auto-analyzer (Hitachi 717, Boehringer Mannheim) using
a routine calorimetric method. Urinary excretions of hydroxyproline and cal-
cium were calculated as the means of two 24-hours collections, related to
creatinine excretion, on a gelatine-restricted diet starting 2 days before the urine
collections. Hydroxyproline was determined colorimetrically at lambda = 560
nm (Hypronosticon, Organon Technika) after hydrolysis during 16 hours at
100°C and oxydation. The analytical coefficient of variation of hydroxyproline
determinations was 13.4% in the normal range. Urinary calcium was deter-
mined colorimetrically at lambda = 546 nm (Hitachi 717, Boehringer Man-
nheim). Bone density was measured in the non-dominant forearm by single
photon absorptiometry (Nuclear Data ND 1100 A, USA). Results are expressed
in arbitrary units per square centimeter (U/cm^). The coefficients of variation of
repeated measurements for the distal and proximal forearm bone density were
3.1% and 1.9%, respectively.
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The results are presented as means ± SEM of absolute values or percentages
of base-line values. Differences between means were tested with ANOVA The
changes of the parameters against time were analyzed with the best fitting
regression analysis. An assigned significance level of 0.05 was used.
RESULTS
Treatment group
In the group of treated subjects a significant ( P < 0.01) decline in mean FT4
ÏÏ ^ m T n «H™; * ^  •"» "" — "* ™ « " * " ' ÏH -i' , TSH-value increased to the objected level although some
individual values rose to the hypothyroid range (fig.1) Three months after the
onserof methimazole therapy 3 subjects still b i i ^ ' ^ ^ o i ^ u ï
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Mean (± SEM) serum FT4 and TSH values in postmenopausal women with subclinical
hyperthyroidism during treatment with methimazole (FT4: solid circles; TSH: bars) or no
treatment (FT4: open circles). All FT4 values in treated women are different frome base-line
200
1.5 9 12 15 18 21 24
months
Mean (± SEM) percentage of base-line concentration of serum osteocalcin (open circles) and
24 hours-urinary hydroxyproline/creatinine ratio (solid circles) in postmenopausal women with
subclinical hyperthyroidism during treatment with methimazole. The regression of 24hours-
urinary hydroxyproline/creatinine ratio against time is significant (y = 1/(O.U1U4 + U.UUWXJ,
= 0.36; P< 0.001).
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DISCUSSION
The cumulating evidence that exogenous subclinical thyrotoxicosis exerts un-
desirable effects on bone has forced monitoring of thyroid replacement therapy
within a strict euthyroid range (5,6). It is not known, however, whether thyros-
tatic treatment of spontaneous subclinical hyperthyroidism is benificial. Al-
though the number of subjects in this study was too small to observe
between-group differences, some interesting longitudinal observations have
emerged from the available data.
Information on bone turnover during thyrostatic treatment is scanty. Some
authors have described a rapid normalization of elevated osteocalcin levels in
thyroid hormone excess when euthyroidism was restored (7,8). In a recent study
in a small group of subjects, however, a discrepancy was observed between a
rapid decline in urinary excretion rates of pyridinium cross-links and unchanged
elevated serum osteocalcin levels during the first 3 months after radioiodine
therapy for hyperthyroidism (9). Another study, in children, has indicated that
serum osteocalcin levels may remain elevated up to a year after the onset of
thyrostatic treatment (10). Earlier observations on serum alkaline phosphatase
levels in hyperthyroidism have shown that thyrostatic treatment induces an
initial increase followed by a slow decline in serum levels of alkaline phos-
phatase (11 - 13). In contrast, urinary hydroxyproline excretion rapidly declines
after institution of thyrostatic treatment (11,12). Our present data in subclinical
hyperthyroidism show that urinary hydroxyproline excretion was inversely
correlated with time since onset of thyrostatic treatment (P < 0.05), while both
serum osteocalcin and alkaline phosphatase levels remained unchanged dunng
the observation period. As bone turnover follows an orderly chronological
organisation of activation, resorption and formation, it is well recognized that it
generally takes several months for therapeutic interventions to normalize the
rate of bone turnover (14 - 16). Although the frequency of bone remodeling
cycles in thyroid excess is increased (16), in older adults it may take a full year
for the remodeling balance to reach a new equilibrium after a therapeutic
intervention (15). The discrepancy between the lack of change in the parameters
of bone formation and the decline in urinary hydroxyproline excretion may
indicate a dissociation between bone formation and bone resorption in favour of
the former.
As in the untreated state (Chapter 5), serum osteocalcin and alkaline phos-
phatase concentrations were correlated during thyrostatic treatment.
In contrast to observations during treatment of overt hyperthyroidism (11,12,
17) urinary calcium excretion did not change during treatment of subclinical
hyperthyroidism with methimazole in the present study. This may be due to an
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interfering effect of thyrostatic treatment on serum PTH levels, resulting in an
altered urinary calcium excretion (18). This possibility was, however, not
further explored in this study.
In the treated subjects no change in forearm bone density was noted during
the observation period. The expected physiological loss of bone in these
postmenopausal women seemed to be compensated by an unchanged bone
formation activity in the face of a declined bone resorption rate. In contrast the
untreated group showed a steady decline in forearm bone density which was
significant for the distal site. Since the rate of physiological bone loss in
postmenopausal women is highly dependent on years since menopause (19-21)
we cannot indicate if the observed decline in bone density in these subjects was'
supraphysiological, as no data on bone loss in age matched euthyroid controls
were available.
In conclusion thyrostatic treatment with methimazole in postmenopausal
subclinical hyperthyroid women with multinodular goitre results in a decline in
osteoclastic bone resorption with unaltered bone formation, as was judged by a
significant decline in urinary hydroxyproline excretion, while the parameters of
bone formation did not change. The benificial effect of thyrostatic treatment on
bone was illustrated by a stable bone density during the treatment period,
despite the postmenopausal status of the treated subjects. In contrast, a gradual
loss of bone density was observed in untreated postmenopausal women with
subclimcal hyperthyroidism. The question whether bone density during thyro-
static treatment will be stabalized at a normal level for age and menopausal
status in the long-run needs further investigation
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Chapter 8
GENERAL DISCUSSION
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8.1 INTRODUCTION
Subclinical hyperthyroidism is defined as a TRH-resistant TSH suppression,
together with normal serum levels of thyroid hormones (Gemsenjager et al,
1976). Recently an increased frequency of nervous symptoms has been ob-
served in subjects with subclinical hyperthyroidism (Schlote et al., 1992). This
Chapter focuses on the somatic aspects of subclinical hyperthyroidism. The
results of the surveys described in this thesis will be discussed in relation to the
available data in the literature.
8.2 TSH AND THYROID HORMONES
The development of immuno-radiometric TSH assays has contributed to a
better discrimination between hyperthyroidism and euthyroidism. In com-
parison with the traditional TSH-RIA's these and other socalled "second
generation" TSH assays have a markedly improved sensitivity, which has made
the determination of the serum concentration of TSH a first line thyroid function
test, at least in an outpatient setting. In hospitalized patients, frequently suffer-
ing from other diseases, this strategy may be less effective, mainly because of
varying results of TSH determinations obtained in "non-thyroidal illness"
(Ehrmann et al., 1989, Nicoloff and Spencer, 1990, Surks et al., 1990, DeGroot
and Mayer, 1992). As was shown in Chapter 2 hyperthyroidism is almost
definitely excluded if the serum TSH concentration, measured by a "second
generation" IRMA, is above 0.1 mU/1. A suppressed TSH (TSH < 0.1 mU/1)
appeared to be highly predictive for a blunted response of TSH to TRH, which
finding is consistent with data reported in the literature on this subject (Seth et
al., 1984, Gibold et al., 1986, Wiersinga et al., 1986, Caldwell et al., 1987).
Wiersinga et al. (1986), however, have shown that in some subjects with a
subnormal response of TSH to TRH, basal serum TSH concentrations,
measured by IRMA, may not be fully suppressed. The reverse, intact TSH
response to TRH at basal serum TSH levels < 0.1 mU/1, may also occur, as has
been shown with a "third generation" TSH assay (Spencer et al., 1990). The
sensitivity of the "third generation" TSH assays is about 10-fold increased in
comparison with the "second generation" assays. It is likely that with these
recently developed "third generation" TSH assays the discrimination between
suppressed and TRH-responsive TSH values can be made even better than with
the "second generation" TSH assays. This would probably result in a better
demarcation between euthyroidism and thyroid autonomy (Spencer et al., 1990,
Hashimoto et al., 1991). According to Bayes theorem, however, the predictive
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value of a suppressed TSH level for overt hyperthyroidism is dependent of the
prevalence of thyrotoxicosis in the population, as can also be drawn from the
data in Chapter 2 and has been shown by others (Hennemann et al., 1987).
In multinodular goitre a substantial number of subjects is discovered with
suppressed serum TSH levels and values for serum thyroid hormone concentra-
tions within the normal range. The question arises whether these subjects should
be regarded as "underway" to hyperthyroidism (i.e."subclinical" hyperthyroid)
or as overt thyrotoxic. Within one individual the level of serum thyroid hor-
mones is kept stable throughout life, within a range that is much smaller than
the reference range in the healthy population (Larsen, 1982, Nicoloff and
Spencer, 1990, Gambert, 1991). A minor increase in the physiological serum
thyroid hormone levels causes suppression of TSH secretion (Larsen et al.,
1982, Spencer et al, 1990). There seems to be an interindividually different
setpoint of thyroid hormone levels at which TSH secretion becomes suppressed
(Spencer et al., 1990, Nicoloff and Spencer, 1990).The level of serum thyroid
hormones in subclinical hyperthyroidism is discussed in several studies. In the
present survey (Chapter 4 and 5) and in other studies (Emrich and Bahre, 1978,
Berghout et al., 1990, Parle et al, 1992) women with multinodular goitre and
suppressed TSH appeared to have a slightly higher level of serum FT4 than
euthyroid women with goitre. This argues not only for interindividual differen-
ces of TSH-sensitivity for thyroid hormones, but also suggests that the "normal"
reference range of FT4 is smaller than usually considered. This seems to be
confirmed by the range of FT4 which we observed in healthy women (Chapter
3). Some authors have reported a slightly elevated mean serum T3 level in
subjects with subclinical hyperthyroidism (Evered et al., 1974, Smeulers et al.,
1977, Emrich and Bahre, 1978). This has not been confirmed, however, by
others (Gemsenjager and Girard, 1983, Berghout et al., 1990). Berghout et al.
(1990) have described that subjects with multinodular goitre have slightly
higher serum total T3 values within the normal range than euthyroid subjects
without goitre, but they did not find a difference between those with normal and
those with suppressed TSH levels.
In conclusion subjects with multinodular goitre and subclinical hyper-
thyroidism may have serum thyroid hormone concentrations within the refer-
ence range, which are inadequately high for their individual needs, as is
indicated by suppressed serum TSH levels and a slightly elevated median serum
FT4 concentration.
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8.3 SOME METABOLIC VARIABLES
Circulating levels of thyroid hormones do not universally reflect cellular con-
centrations as was shown in vitro in rats (Obregon et al., 1979, Van Doorn et al.,
1985) and made plausible in human studies (Larsen et al., 1982). Local conver-
sion of T4 to T3 differs widely between the various target organs of thyroid
hormones (Van Doom et al., 1985). There is a remarkable difference in local
production of T3 between the hypothalamus and anterior pituitary gland, both
of which are involved in the feedback with the thyroid gland, although in both
systems the local conversion is much higher than in most peripheral tissues, as
was shown in rats (Van Doorn et al., 1985). Physiologically, circulating T4
seems to be more important than T3 in the feedback system (Larsen et al., 1982,
Spencer et al., 1990). It is not known whether the intracellular level of T3 in
subjects with suppressed TSH and normal circulating thyroid hormone levels is
increased. Some metabolic aspects, however, suggest that this might indeed be
the case.
Serum levels of sex hormone binding globulin (SHBG), which is supposed to
be a marker of tissue activity of thyroid hormones, are elevated both in endo-
genous subclinical hyperthyroid subjects and in subjects treated with suppres-
sive doses of L-thyroxine (Faber et al., 1990a, Faber et al., 1990b, Giagulli and
Vermeulen, 1992). Serum levels of SHBG correlate with serum TSH concentra-
tions (Faber et al., 1990b, Jarl0v et al., 1992).
Increased serum levels of 5a-androstane-3a, 17p-diolglucuronide have been
documented in postmenopausal women with suppressed TSH and normal serum
thyroid hormone levels, indicating an increased thyroid induced 5<x-reductase
activity in the liver in subclinical hyperthyroidism (Giagulli and Vermeulen,
Recently a decreased mean total serum cholesterol level has been described
in subjects with suppressed TSH and normal thyroid hormone levels. (Parle et
al., 1992). Serum LDL cholesterol levels, however, appeared to be unchanged.
In conclusion these data indicate that some biochemical markers of
peripheral thyroid hormone activity are increased in subclinical hyper-
thyroidism.
8.4 BONE TURNOVER
In this survey serum osteocalcin levels, a parameter of bone turnover, were
studied in relation to subclinical hyperthyroidism. In healthy women serum
osteocalcin levels appeared to vary with age, showing a decline in adult life,
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which reached a nadir in the fourth decade, followed by an increase around the
aee of 50 years (Chapter 3). Although there is some variance in the data
concerning age related changes in serum osteocalcin the pattern that was found
in this study was not essentially different from most of the reported data
melmas et al., 1983, Epstein et al., 1984, Worsfold et al., 1988, Duda et al.,
1988 Tarallo et al., 1990, Vanderschueren et al., 1990). From these -transver-
sal- observations it appears that the serum osteocalcin level increases in the
nerimenopausal period. In one of the earliest reports on serum osteocalcin levels
£ healthy females, however, a negative correlation between serum osteocalcin
values and age was observed (Price et al., 1980b). Since osteocalcin is a vitamin
K dependent protein this discrepancy might be due to a difference in vitamine
K levels in these subjects. Data on the vitamin K status, however, are not
available in these reports. Knapen et al. (1989) have shown that serum osteocal-
cin levels in apparently healthy postmenopausal women increase to higher than
premenopausal values only after vitamin K administration.
The available data concerning serum osteocalcin levels in subchnical
thyrotoxicosis are largely derived from subjects treated with suppressive doses
of L-thyroxine. These data are not unequivocally. The discrepancy in results
between some of these studies is reviewed in Chapter 5. In endogenous subchni-
cal hyperthyroidism information about osteocalcin levels is scanty. In the
present survey, in a cross-sectional study in 77 women with multinodular goitre,
higher levels of serum osteocalcin were found in those with suppressed TSH
than in the euthyroid subjects (Chapter 5). Expression of the data as Z-scores
revealed that the increase in osteocalcin levels in women with subchnical
hyperthyroid multinodular goitre in comparison with euthyroid goitre subjects
was not due to age (Chapter 5). These data are in agreement with those of Faber
et al (1990b), which also have indicated that serum osteocalcin is elevated in
spontaneous subclinical hyperthyroidism. Like Faber et al. (1990b) and Ross et
al (1991c) no correlation between osteocalcin (expressed as Z-scores) and
serum thyroid hormones in women with subdinical hyperthyroid multinodular
goitre could be established, although positive correlations between both ab-
L u t e and relative (as Z-scores) osteocalcin values and1 FT4 wen> observed
when the data of the subclinical hyperthyroid and euthyroid goitre subjects were
t f o * of the clinical studies on osteocalcin up to now have been performed
with heterologeous immuno-assays. The recently developed ™ ™ ^ » » £
raised against human osteocalcin probably may offer a more reliable quanuta-
tion of bone formation than the bovine assay we have used in the present study
(Kanzaki et al., 1992).
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Not only osteocalcin, but also the median concentration of serum alkaline
phosphatase appeared to be higher in women with subclinical hyperthyroid
multinodular goitre than in women with euthyroid goitre, although individual
values were all within the normal range (Chapter 5). Beside these indications of
increased osteoblastic function in subclinical hyperthyroidism, recently an in-
creased osteoclastic activity in postmenopausal women during suppressive
L-thyroxine treatment was substantiated by the demonstration of increased
urinary excretion of pyridinium cross-links in these subjects (Harvey et al.,
1991). These indications of increased parameters of both osteoblastic and'
osteoclastic activity in subclinical thyrotoxicosis suggest an increased activa-
tion frequency of bone remodeling units in this condition. In overt
thyrotoxicosis a negative balance between bone formation and resorption is
supposed (Meunier et al., 1972, Melsen and Mosekilde, 1977, Eriksen et al.,
1985). It should be noticed, however, that the data of Eriksen et al. (1985) were
based on extrapolation of the appositional growth curve. The actually measured
maximal completed wall thickness in thyrotoxic trabecular bone in this par-
ticular study, however, was not different from normal. Nevertheless, even if
there would not be an imbalance between bone formation and resorption in a
state of mild thyroid hormone excess, the increased bone turnover rate in
subclinical hyperthyroidism would still result in accelerated loss of bone, since
there is a physiological imbalance between osteoblastic apposition and os-
teoclastic resorption in older adult women (Parfitt 1979, Parfitt 1986).
In conclusion the data obtained in women with endogenous subclinical
hyperthyroid multinodular goitre point to an increased bone turnover rate in this
condition. A combination of measurements of human osteocalcin with te newer,
more sensitive and specific parameters of osteoclastic activity, like tartrate
resistant acid phosphatase (Lau et al. 1987, Stepan et al., 1989, Kraenzlin et al.,
1990) and pyridinium crosslinks (Delmas et al., 1991, Hassaet al., 1992, Uebel-
hart et al., 1992, Harvey et al., 1992) would possibly offer more insight in the
extend to which bone turnover is increased in subclinical hyperthyroidism.
8.5 BONE DENSITY
Fracture risk scores and assessments of clinical and biochemical parameters of
bone density have not a high predictive value for the occurrence of fractures
(Elders et al., 1989, Van Hemert et al., 1990). In contrast, direct measurement
ot bone density, as performed with single photon absorptiometry, is a reliable
method to predict fracture risk (Hui et al., 1988, Hui et al., 1989, Melton et al.,
1990, Johnston et al., 1991). In Chapter 4 we have shown that women with
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multinodular goitre who expose a suppressed TSH in combination with normal
Trum thyroid hormone levels have decreased Z-scores of forearm bone density
Comparison with euthyroid goitre women. No other reports on bone density
in endogenous subclinical hyperthyroidism are available up to now.
Recently, several editorials in main clinical journals have addressed the
possible adverse effects of oversubstitution of thyroidhormones; onbone|dea-
£ y (Perry 111 et al., 1986, Burman, 1990, Franklyn and Sheppard, 1990, Baran
and Braverman, 1991, Toft, 1991, Ross, 1991a). This commotion was induced
« r e e e n papers concerning photon-absorptiometric determinations of
bonTTensity indLting bone loss due to subclinical thyrotoxicosis induced by
LThy?oxme"'therapy. In one of the first of these reports 3 case histories of
t lh r i n e treated'postmenopausal women w^i fractures and * * ^
confirmed osteoporosis have been described (Fallon et al., 1983). Actually
hes subjects were substituted in a mild thyrotoxic range. Additional - p o m
-some of which are summerized here- in subjects on L-thyroxine treatment have
i dicated that substitution to a level at which TSH becomes suppressed may 1*
harmful to bone metabolism, despite serum thyroid hormones are within the
n Z a l range Rossetal (1987) have described a significant inverse correlation
Z i n learnt bone density and years f / f ^ ^ e s e
premenopausal women. The mean serum level of thyroid hormones m ttese
subjects was only slightly above normal. A similar relation has beer«dekbed
between duration of suppressive L-thyroxine treatment and ^ e density in the
calcaneus (Lehmke et al., 1992). There is still controversy abou t « « t e n d to
which bone is lost and the influence of menopause ^ " " g oversubstitut^n of
L-thyroxine to a level of suppressed TSH. Taelman et al. (1990) have: reported
a 20% reduction in both proximal and distal forearm bone density m
postmenopausal women treated for 10 years with suppressive «
thyroxine In contrast, in premenopausal women the reduction, „
forearm bone density, was only 5%, whereas * ^ / « ^ ^
reduced in these subjects. The course of treatment of the P
jects, however, was half the duration in the postmenopausal ^ ^
Pun 1991) have found significantly reduced bone densities in the^  fernond neck
trochanter Wards triangle, forearm and pelvis but not in ^ a x a l skeleton n
premenopausal women treated with L-thyroxine. The s e w n ^ s « b*h
thyroid hormones and TSH in the treated subjects were comparable w th age
matched controls. The TSH-assay used in this particular study, howeve^ ™s .
d diriiation ^ ^ " ^ ^ ^ 5 ^
matched controls.  y
RIA. making a goo  iscrimination ^ ^ , ^ ^
i h d ulation impossible Lehmke etRIA. making a g ^ ^ , ^ ^ ^ 5 ^ ^
thyrotoxicosis in the study population impossible. Lehmke et aL (1992) na
reported normal bone density in the forearm and axial ske ^ n c o n t t a r t t o a
reduced density in the calcaneus in L-thyroxine treated subchnical thyrotoxic
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premenopausal females. Comparable data of decreased peripheral bone density,
but normal axial bone density have been described in L-thyroxine treated
postmenopausal women (Paul et al., 1988, Lehmke et al., 1992). Chabert-Orsini
et al. (1990) could not find either a decline in lumbar bone density in a mixed
population of premenopausal and postmenopausal subclinical thyrotoxic
women on L-thyrotoxine treatment. In contrast, more exaggerated loss of bone
in the axial than in the peripheral skeleton has been described by others, both in
pre- and postmenopausal women treated with L-thyroxine (Stall et al., 1990,
Pioli et al., 1992). A different effect of thyroid hormone excess on cortical and
trabecular bone may well be possible, as was suggested earlier by Meunier et al.
(1972) based on histomorphometric studies. In other endocrine bone disease,
like in hyperparathyroidism, also a differentiated effect on bone density has
been observed (Silverberg et al., 1989). At this stage, however, the available
data are too conflicting to decide which type of bone is preferentially suscep-
tible to mild thyroid hormone excess.
Even institution of thyroid hormone replacement therapy in hypothyroidism
has been reported to induce loss of bone mass, at least in the first year of
treatment (Kr0lner et al., 1983, Coindre et al., 1986, Ribot et al., 1990). It is not
known, if this initial increase in bone loss during L-thyroxine replacement
therapy is followed by a "catch-up" bone formation phase in the following
years, although Tremollieres (1992) recently has reported a follow-up study
which has indicated a complete bone recovery at the spine but not at the femoral
neck in the second year of treatment. The studies indicating initial loss of bone
during institution of thyroid replacement therapy have been performed in mixed
populations of males and females, the women outnumbering the men. A com-
parable study in a population consisting of only men could not confirm these
data during a 3 years follow-up (Toh and Brown, 1990).
Speculations have been made about a possible role of thyrotoxicosis in the
distant past as a cause of the L-thyroxine related bone loss. In two recent studies
it was found that exclusion of subjects previously treated for thyrotoxicosis
abolished the difference in bone density between L-thyroxine treated subjects
and controls (Greenspan et al., 1991, Adlin et al., 1991). It could be argued,
however, that in the remaining study groups the number of subjects was too
small to show a significant difference in bone density. In another recent study
(Franklyn et al., 1992), in which a negative effect of L-thyroxine treatment on
bone density is disputed, 29% of the treated subjects had non-suppressed serum
TSH-levels. This particular study may actually indicate that if L-thyroxine
substitution is carefully monitored no loss of bone would be induced.
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In some studies a contributing role of calcitonine deficiency to bone loss
during L-thyroxine treatment, especially in totally thyroidectomized subjects,
was suggested (McDermott et al., 1983, Lowery et al., 1986, Diamond et al,
1990, Gonzalez et al., 1991, Adlin et al., 1991). In a comparison of subjects with
elevated calcitonine levels after thyroidectomy for medullary thyroid carcinoma
with subjects with decreased calcitonine secretory reserve because of subtotal
thyroidectomy for benign disease Hurley et al. (1987), however, could not
establish a bone-conserving role for calcitonine.
From all of these studies it may be concluded that longterm L-thyroxine
treatment is only associated with decreased bone density, when TSH becomes
suppressed. This seems especially true in postmenopausal women. We found
that Z-scores of forearm bone density are inversely correlated with serum levels
of FT4 in women with suppressed TSH and normal thyroid hormone levels
(Chapter 4). No such correlation was found in the euthyroid goitre controls. In
healthy women no correlation between forearm bone density and thyroid func-
tion was found either, although there was a tendency to an inverse correlation
between forearm bone density and serum TSH (Chapter 3). These data illustrate
the value of TSH as a marker for tissue thyroid hormone exposure: serum FT4
seems to be only indicative for the thyroid status at the level of the skeleton
when TSH becomes suppressed.
Although decreased bone density is correlated with increased fracture risk
(Hui et al., 1989 ), a prospective study of fracture rate in subjects with en-
dogenous subclinical hyperthyroidism would be required to substantiate the
clinical significance of the finding of reduced forearm bone density in women
with subclinical hyperthyroidism. It would also be of interest if other clinical
relevant sites of the skeleton, like the femur and the vertebrae, also show
decreased bone density in endogenous subclinical hyperthyroidism. In a recent
survey of 1180 patients on L-thyroxine replacement therapy no significant
increase in fracture rate was observed in those with suppressed TSH, although
there was a trend to a higher incidence of fractures in people over 65 years
compared with those who had a normal TSH (Leese et al., 1992). In this
particular study, however, only major fractures, requiring hospital admission
were considered, which neglects clinically important fractures, like Colles
fracture.
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8.6 THE HEART
In Chapter 6 is described that women with multinodular goitre who combine
suppressed TSH levels with normal levels of thyroid hormones have a slight
increase in heart rate without altered cardiac performance as was measured by
PEP/LVET ratios. The finding of an increased heart rate is consistent with data
of Boutin et al. (1983) who have described that heart rate in subjects with
endogenous subclinical hyperthyroidism was midway between euthyroid and
hyperthyroid subjects.
The PEP is physiologically represented by the isovolumetric contraction
time, which is dependent on heart rate, preload, afterload, stroke volume and
ventricular contractility (Weissler et al., 1968, Hirschfeld et al., 1976). Of these,
the influence of heart rate is rather small (Weissler et al., 1968, Amidi et al.,
1968). Analysis of the different components of the isovolumetric contraction
time by Amidi et al. (1968) have shown that the decrease in PEP in hyper-
thyroidism is mainly the result of an increased myocardial contractility. The
LVET is a function of heart rate, stroke volume, mean arterial pressure and
ventricular contractility (Weissler et al. 1968, Amidi et al., 1968). Likewise,
Amidi et al. (1968) have analyzed that the increase in LVET in hyperthyroidism
is largely due to an increased inotropic state. The findings in the present study,
combined with these earlier observations suggest that in thyroid hormone
excess an increased chronotropy predominates over an increased inotropy. This
is in agreement with the finding that the evelated cardiac output during excer-
cise in thyrotoxis is entirely due to an increased heart rate, while stroke volume
is not different from normal (Martin III et al., 1991). Moreover, the LVET may
actually decrease during excercise in thyrotoxicosis, in contrast to an increase
in euthyroidism (Forfar and Caldwell, 1985).
The clinical relevance of altered cardiac function in subclinical hyper-
thyroidism is illustrated by a high prevalence of atrial fibrillation, as has been
documented in a Swedish population with endogenous subclinical hyper-
thyroidism (Tenerz et al., 1990). Conversely in selected patients presenting with
atrial fibrillation subclinical hyperthyroidism may be the underlying condition
(Forfar et al., 1979, Bruce et al., 1987). Especially eldery people with multi-
nodular goitre seem to be at risk for this cardiac arrythmia (Forfar et al., 1979,
Bruce et al., 1987, Tenerz et al., 1990). Thyrostatic treatment results in return
to sinus rhythm, although cardioversion may be needed (Forfar et al., 1981).
A recent study showed an increased risk of ischaemic heart disease in
subjects under the age of 65 years on L-thyroxine treatment, but the risk was not
different between those with suppressed and normal TSH (Leese et al., 1992).
This situation, however, might not be comparable with endogenous subclinical
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hyperthyroidism, since L-thyroxine substituted subjects might have ex-
perienced elevated serum cholesterol levels during a preceding phase of
hypothyroidism. On the other hand decreased serum cholesterol levels in en-
dogenous subclinical hyperthyroidism (Parle et al., 1992) might increase after
thyrostatic treatment, which would possibly influence the risk of myocardial
infarction. The net effects of these different influences and the effects of
thyrostatic treatment on cardiac morbidity and mortality in endogenous sub-
clinical hyperthyroidism should be evaluated in a prospective study.
8.7 THYROSTATIC TREATMENT
In Chapter 7 the results of thyrostatic treatment of 8 postmenopausal women
with multinodular goitre and suppressed TSH in combination with normal
serum thyroid hormone levels on some parameters of bone metabolism are
described during a 2 years follow-up period. The data were compared with those
in 8 untreated postmenopausal women with the same condition. It appeared that
during thyrostatic treatment neither the serum osteocalcin nor the alkaline
phosphatase levels changed significantly. The absence of a change in
parameters of osteoblastic function contrasts with the rapid decline in unnary
hydroxyproline excretion which was observed soon after the onset of thyrostatic
treatment. Noting that activation of bone remodeling units always starts at the
level of the osteoclast (Frost, 1969, Parfitt, 1979, Parfitt, 1986), it is not
surprising that a decline in osteoblastic parameters may be delayed. Specula-
tively a possible mechanism for the absence of a decline in the parameters of
osteoblastic function could be supposed by a return of depressed PTH levels to
normal values during thyrostatic therapy (Ross et al., 1989b). This in its turn
could restore the suppressed levels of 1,25 dihydroxyvitamin D3, which is the
main activator of osteocalcin production by the osteoblast (Bouillon et al., iy»u,
Morrison et al., 1989). This possible sequence of events, however, was not
explored in this study.
The elevated serum osteocalcin levels in the dynamic phase of thyrostatic
treatment should be interpreted different from that in the stable phase ot
subclinical hyperthyroidism. In the last situation the increase m osteocalcin
reflects increased bone turnover, which results in continuing bone loss, as was
shown in the 8 postmenopausal women who received no thyrostatic treatment.
In the former situation, however, the discrepancy between the lack of change in
the parameters of bone formation and the decline in urinary hydroxyproline
excretion seems to illustrate the conservation of bone density dunng thyrostatic
treatment.
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8.8 CONCLUSIONS
. The second generation IRMA-TSH is a useful firstline thyroid function test in
the diagnosis of hyperthyroidism in an outpatient setting of subjects who are
suspected for hyperthyroidism. Serum TSH values > 0.1 mU/1 almost definitly
exclude hyperthyroidism.
. In healthy women neither bone metabolism nor forearm bone density is in-
fluenced by the level of thyroid function within the normal range.
• The existence of correlations both between the serum osteocalcin concentration
and age and between forearm bone density and age accounts for the correlation
between the serum osteocalcin concentration and forearm bone density. There-
fore, the serum osteocalcin concentration is not a useful parameter of bone
density.
. In women with untreated multinodular goitre the existence of a suppressed basal
serum TSH level is indicative for hyperthyroidism, irrespective of the level of
thyroid hormones, as was shown by increased serum concentrations of osteocal-
cin and alkaline phosphatase, decreased forearm bone density and increased
heart rate in these subjects.
. Thyrostatic treatment with methimazole of postmenopausal women with sub-
clinical hyperthyroid multinodular goitre results in a decline in bone resorption
without a change in bone formation during the first two years of treatment.
. During thyrostatic treatment forearm bone density in postmenopausal women
with subclinical hyperthyroid multinodular goitre is stabilized, while bone loss
in untreated women is continued.
. The data on bone metabolism and cardiac function observed in women with
subclinical hyperthyroid multinodular goitre indicate that "subclinical" hyper-
thyroidism is not essentially different from "overt" hyperthyroidism and should
be treated as such.
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SUMMARY
In CTzapter 7 the concept of subclinical hyperthyroidism is discussed and the
influence of thyroid hormones on bone and heart is summarized. The aim of this
study was to explore the impact of spontaneous subclinical hyperthyroidism on
some target tissues. Bone, as a slow changing parameter, and the heart, as a fast
changing parameter, were chosen as target tissues. The group of interest con-
sisted of females with multinodular goitre.
In CTia/Jter 2 a survey is described in which the value of a "second genera-
tion" immuno-radiometric assay (IRMA) of TSH as a first line thyroid function
test was defined in 36 subjects suspected for hyperthyroidism. Seventeen of
these subjects had a subnormal response in the TRH-test (increase, measured by
a radio-immuno assay (RIA), in TSH less than 1.0 mU/1). At a discrimination
value of TSH = 0.1 mU/1 basal TSH-IRMA appeared to have a very high
predictive value for the outcome of the TRH-test (positive and negative predic-
tive value 1 and 0.95, respectively). In the subjects with a normal response in
the TRH-test (n = 19) basal TRH-IRMA correlated closely with the increase in
TSH (measured by RIA) after TRH stimulation (y = 0.13 + 0.13x; r = 0.897; P
< 0.001). Based on these data "subclinical hyperthyroidism" was defined as
suppressed basal serum TSH (= basal TSH < 0.1 mU/1) in combination with
normal serum thyroid hormone levels.
In CTiapter i the interrelationships between serum osteocalcin, forearm bone
density (measured by single photon absorptiometry), thyroid function
parameters, age and body mass are explored in a cross-sectional study in 125
healthy women, aged between 21 and 75 years. Measurements in two different
periods of a year showed neither differences in serum osteocalcin values nor in
parameters of thyroid function. The serum concentration of osteocalcin was
independently correlated with age and body mass index (osteocalcin =
9.774571 + 0.080023 age O) - 0.12621 body mass index©, multiple r = 0.39;
P O < 0.0001, P(2) = 0.013). No correlations were found between osteocalcin
and thyroid function parameters. Inverse correlations between osteocalcin and
both proximal and distal bone density appeared to be determined by age related
variations in both parameters. The best fitting correlation between serum osteo-
calcin and age was obtained with cubic regression analysis (y = 23 86536 -
1.080274x + 0.024269x2 - 0.000161x3; r = 0.39; P = 0.0002). Also the relation
between distal, respectively proximal, forearm bone density and age was best
described with cubic regression analysis (y = 0.974144 - 0 002408x +
0.000227x2 - 0.000004x3; r = 0.59; P < 0.0001 and y = 1.506425 - 0.020131x +
110
0.000674 x2 - 0.000007x3; r = 0.65; P < O.OOO1, respectively). There were no
independent correlations between forearm bone density and thyroid function
parameters.
It is concluded that in healthy women the level of thyroid function has no
influence on bone metabolism, nor on bone density. Since age related variations
in both the serum osteocalcin concentration and forearm bone density account
for the correlation between these two parameters it is concluded that the serum
osteocalcin concentration is not a good parameter for bone density.
In Ctepfer 4 forearm bone densities in 23 women with subclinical hyper-
thyroid multinodular goitre are compared with those in 54 women with
euthyroid multinodular goitres. The data were expressed as Z-scores related to
the data in the 125 healthy females described in Chapter 3. The subclinical
hyperthyroid subjects were significantly older than the euthyroid subjects
(median (range) ages 57.2 (37-70.7) years vs48.6 (24-69.8) years; P < 0.01) and
had a significantly higher median (range) serum FT4 concentration (15.6 (11-
23.2) pmol/1 vs 11.9 (8.3-18.3) pmol/1; P < 0.001). Mean (± SEM) Z-scores of
both distal and proximal bone density appeared to be lower in the subclinical
hyperthyroid than in the euthyroid goitre subjects (- 0.69 ± 0.17 vs - 0.1 ± 0.18;
P < 0.05 and - 0.5 ± 0.18 vs 0.07 ± 0.18; P < 0.05, respectively). In contrast to
what was found in the euthyroid subjects, FT4 correlated inversely with Z-
scores of both distal and proximal forearm bone density in the subjects with
subclinical hyperthyroidism (r = - 0.42; P < 0.05 and r = - 0.45; P < 0.05,
respectively).
In Ctep/er 5 serum osteocalcin and alkaline phosphatase concentrations in
the subjects described in Chapter 4 are compared. Both median (range) os-
teocalcin and alkaline phosphatase concentrations in serum were higher in the
subclinical hyperthyroid than in the euthyroid multinodular goitre subjects
(12.4 (6.7-19.6) p.g/1 vs 9.9 (4.6-18.8) ^gA; P = 0.01 and 74 (42-95) U/l vs 55
(29-94) U/l; P = 0.0034, respectively). Expression of the osteocalcin data as
Z-scores revealed that the difference in serum osteocalcin concentrations was
not due to the difference in age between the groups (median (range) Z-score of
osteocalcin in subclinical hyperthyroid vs euthyroid goitre subjects 0.33 (- 1.57
to 3.83) vs - 0.16 (- 2.84 to 3.13); P = 0.0225). Both in the euthyroid and in the
subclinical hyperthyroid subjects osteocalcin correlated significantly with
alkaline phosphatase (r = 0.51; P < 0.001 and r = 0.45; P = 0.0313; respectively).
These data indicate that bone turnover in women with subclinical hyperthyroid
multinodular goitre is increased in comparison with euthyroid multinodular
goitre subjects.
I l l
In C/ia/>fer 6 a survey is described in which some cardiac effects of en-
dogenous subclinical hyperthyroidism are explored in a cross-sectional study in
27 women with subclinical hyperthyroid multinodular goitre and in 27 women
with euthyroid multinodular goitre. Systolic time intervals, expressed as the
ratio of the pre-ejection period (PEP) to the left ventricular ejection time
(LVET), were measured from simultaneous electrocardiographic and M-mode
echocardiographic tracings, obtained from a two-dimensional echocardiogram.
No significant difference between the mean (± SD) PEP/LVET ratios in the two
groups was observed (0.266 ± 0.049 vs 0.281 + 0.048; N.S.). Mean (+ SD)
resting heart rate, however, was higher in the subclinical than in the euthyroid
multinodular goitre subjects (89.7 ± 12.9 beats/min vs 80 ± 14.4 beats/mhr P =
0.012).
In C/ja/j/er 7 some longitudinal data are presented concerning bone metabo-
lism and forearm bone density in 8 postmenopausal women with subclinical
hyperthyroid multinodular goitre during monotherapy with methimazole. These
data are compared with those obtained in 8 untreated postmenopausal women
with the same condition. The follow-up period in this study was up to 24
months. Thyrostatic treatment in the 8 postmenopausal women with subclinical
hyperthyroidism resulted in a rapid decline in urinary hydroxyproline excretion.
No significant changes in the serum concentrations of osteocalcin and alkaline
phosphatase levels, nor in urinary calcium excretion were observed. In the
treatment group forearm bone density remained stable during the observation
period. In contrast, in the untreated subjects a gradual loss of forearm bone
density was observed, which was significant (P < 0.05) for the distal site. It was
concluded that bone loss in postmenopausal women with subclinical hyper-
thyroid multinodular goitre is settled down by thyrostatic treatment with
methimazole, while it continues if subclinical hyperthyroidism is left untreated.
The studies described in this thesis indicate that "subclinical" hyper-
thyroidism is not essentially different from "overt" hyperthyroidism and should
be treated as such.
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SAMENVATTING
In //oo/d!ïfl<Jt / wordt het begrip "subklinische hyperthyreodïe" besproken en er
wordt een samenvatting gegeven van de invloed van schildklierhormonen op het
bot en het hart. Het doel van het onderzoek beschreven in dit proefschrift was na
te gaan wat de invloed van spontane subklinische hyperthyreoïdie is op enkele
doelorganen van schildklierhormonen. Bot, als een langzaam veranderende para-
meter, en het hart, als een snel veranderende parameter, werden gekozen ais
doelorganen. De onderzoeksgroep bestond uit vrouwen met multinodulair struma.
In #oo/&M 2 wordt het onderzoek beschreven waarin de waarde werd
onderzocht van een "tweede generatie" immuno-radiometrische assay (IRMA)
voor TSH als een initieel schildklierfunctie onderzoek. Dit onderzoek werd
uitgevoerd bij 36 patiënten bij wie het vermoeden op hyperthyreoïdie bestond.
Zeventien van deze patiënten hadden een subnormale respons in een TRH-test
(stijging van TSH, gemeten met een radio-immuno assay (RI A), minder dan 1.0
mU/I). Bij een discriminatiegrens van TSH = 0.1 mU/1 bleek dat een basaal
gemeten TSH-IRMA een zeer hoge voorspellende waarde had voor de uitkomst
van de TRH-test (positief en negatief voorspellende waarde respectievelijk 1 en
0.95). Bij de patiënten met een normale respons in de TRH-test (n = 19)
correleerde de basaal gemeten TSH-IRMA goed met de stijging van TSH
(gemeten d.m.v. RIA) na TRH stimulatie (y = 0.13 + 0.13x; r = 0.897; P <
0.001). Op grond van deze gegevens werd de diagnose "subklinische hyperthy-
reodie" gedefinieerd als een combinatie van een onderdrukte basaal gemeten
serum TSH concentratie (TSH < 0.1 mU/1) en normale serum-concentraties van
schildklierhormonen.
In //oo/dsru* 3 worden de relaties beschreven tussen serum osteocalcine,
botdichtheid van de pols (gemeten door middel van "single photon absorptio-
metry") en parameters van de schildklierfunctie, leeftijd en lichaamsgewicht in
een transversale studie betreffende 125 gezonde vrouwen tussen 21 en 75 jaar.
Metingen in twee verschillende periodes in een jaar toonden geen verschil in
serum-concentraties van osteocalcin, noch van schildklierfunctieparameters.
De serum-concentratie van osteocalcine correleerde onafhankelijk met de leef-
tijd en de Queteletindex (osteocalcine = 9.774571 + O.O8OO23 leeftijd <'> -
0.12621 Queteletindex®, multipele r = 0.39; P<'> < 0.0001, P ^ = 0.013). Er
werden geen correlaties gevonden tussen osteocalcine en schildklierfunctiepa-
rameters. Omgekeerde correlaties tussen osteocalcine en zowel proximale als
distale botdichtheid bleken te worden veroorzaakt door leeftijdsafhankelijke
variaties in beide parameters. De beste correlatie tussen de serum osteocalcine-
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concentratie en de leeftijd werd verkregen met cubische regressie-analyse (y =
23.86536 - 1.080274x + 0.024269x* - 0.000161^; r = 0.39; P = 0.0002). Ook
de correlatie tussen distale, respectievelijk proximale, botdichtheid van de pols
en de leeftijd werd het best beschreven met cubische regressie-analyse (y =
0.974144 - 0.002408x + 0.000227x* - 0.000004x'; r = 0.59; P < 00001
respectievelijk y = 1.506425 - O.O2O131x + 0.000674x2 - 0.000007x ;^ r = 0.65;
P < O.OOOl). Er werden geen onafhankelijke correlaties tussen de botdichtheid
van de pols en parameters van de schildklierfunctie vastgesteld.
Concluderend blijkt dat bij gezonde vrouwen het niveau van de schildklier-
functie noch van invloed is op het botmetabolisme, noch op de botdichtheid.
Aangezien de correlatie tussen de serum-concentratie van osteocalcine en de
botdichtheid van de pols wordt veroorzaakt door leeftijds-afhankelijke schom-
melingen in beide parameters, wordt vastgesteld dat de serum concentratie van
osteocalcine geen goede parameter is van de botdichtheid.
W O O / ^ / M * 4 betreft een studie waarbij de botdichtheid gemeten aan de pols
van 23 vrouwen met subklinische hyperthyreoïdie en multinodulair struma
wordt vergeleken met die van 54 vrouwen met euthyreoïde multinodulaire
strumae. De gegevens werden uitgedrukt als Z-scores gerelateerd aan de waar-
den van de 125 gezonde vrouwen die in Hoofdstruk 3 werden beschreven. De
patiënten met subklinische hyperthyreoïdie waren significant ouder dan de
euthyreoïde patiënten (mediane (spreiding) leeftijd 57.2 (37-70.7 jaar) vs 48.6
(24-69.8 jaar; P < 0.01) en zij hadden een significant hogere mediane (sprei-
ding) serum concentratie FT4 (15.6 (11-23.2) vs 11.9 (8.3-18.3); P< 0.001). Bij
de subklinische hyperthyreoïde patiënten bleek de gemiddelde (± SEM) Z-score
van zowel de distale als de proximale botdichtheid lager te zijn dan bij de
euthyreoïde strumapatiënten (- 0.69 ± 0.17 vs - 0.1 ± 0.18; P < 0.05, respectie-
velijk - 0.5 ± 0.18 vs 0.07 ± 0.18; P < 0.05). In tegenstelling tot de euthyreoïde
patiënten was bij de subklinisch hyperthyreoïde patiënten FT4 omgekeerd
gecorreleerd met de Z-scores van zowel de distale als de proximale botdichtheid
van de pols (r = - 0.42; P < 0.05, respectievelijk r = - 0.45; P < 0.05).
In #OO/S/HA 5 wordt een vergelijking gemaakt tussen de serum-concentraties
van osteocalcine en alkalische fosfatase van de patiënten die beschreven zijn in
Hoofdstuk 4. Bij de subklinisch hyperthyreoïde patiënten waren zowel de
mediane (spreiding) osteocalcine als de mediane (spreiding) alkalische fosfata-
se concentraties in serum hoger dan die van de euthyreoïde multinodulaire
strumapatiënten (12.4 (6.7-19.6) ug/1 vs 9.9 (4.6-18.8) ug/1; P = 0.01, respectie-
velijk 74 (42-95) U/l vs 55 (29-94) U/l; P = 0.0034). Wanneer de osteocalcine-
waarden werden uitgedrukt als Z-scores, bleek dat het verschil in de serum
osteocalcine-concentraties niet werd veroorzaakt door het verschil in leeftijd
tussen de twee groepen (mediane (spreiding) Z-score van osteocalcine van de
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subklinisch hyperthyreoïde vs de euthyreoïde strumapatiënten 0.33 (- 1.57 tot
3.83) vs - 0.16 (- 2.84 tot 3.13); P = 0.0225). Zowel bij de euthyreoïde als bij de
subklinische hyperthyreoïde patinten was osteocalcine significant gecorreleerd
met alkalische fosfatase (r = 0.51; P < 0.001, respectievelijk r = 0.45; P =
0.0313). Deze gegevens wijzen erop dat de botombouw van vrouwen met
subklinische hyperthyreoïdie en multinodulair struma verhoogd is vergeleken
met die van euthyreoïde multinodulaire strumapatiënten.
In /Zoo/isM 6 wordt een onderzoek beschreven waarin enkele cardiale
invloeden van endogene subklinische hyperthyreoïdie werd onderzocht in een
transversale studie bij 27 vrouwen met subklinische hyperthyreoïdie en multi-
nodulair struma in vergelijking met 27 vrouwen met euthyreoïde multinodulaire
strumae. Systolische tijdsintervallen, uitgedrukt als de ratio van de pre-ejectie
periode (PEP) en de linker ventriculaire ejectietijd (LVET), werden gemeten
door middel van gelijktijdige registratie van het electrocardiogram en "M-
mode" echocardiogram, gemeten met een twee-dimensionale echocardiograaf.
Er werden geen significante verschillen waargenomen tussen de gemiddelde (±
SD) PEP/L VET ratio's van de twee groepen (0.266 ± 0.049 vs 0.281 ± 0.048;
N.S.). De gemiddelde (± SD) hartfrequentie in rust was echter hoger bij de
subklinisch hyperthyreoïde dan bij de euthyreoïde multinodulaire strumapatiën-
ten (89.7 ± 12.9 slagen/min vs 80 ± 14.4 slagen/min; P = 0.012).
In //oo/tf.s/«& 7 worden enkele longitudinale gegevens gepresenteerd betref-
fende het botmetabolisme en de botdichtheid van de pols bij 8 postmenopausale
vrouwen met subklinische hyperthyreoïdie en multinodulair struma tijdens
monotherapie met methimazol. Deze gegevens werden vergeleken met die
welke werden verkregen bij 8 onbehandelde postmenopausale vrouwen met
dezelfde aandoening. Dit vervolgonderzoek beslaat een tijdsduur van 24 maan-
den. Thyreostatische behandeling van de 8 menopausale vrouwen resulteerde in
een snelle daling van de hydroxyproline-uitscheiding in de urine. Er werden
geen significante verschillen in de serum-concentraties van osteocalcine en
alkalische fosfatase, noch in de calciumuitscheiding in de urine waargenomen.
In de behandelde groep veranderde de botdichtheid van de pols niet gedurende
de studieduur. In de onbehandelde groep trad echter een geleidelijke daling van
de botdichtheid op, die significant (P < 0.05) was voor de distale meting. Hieruit
blijkt dat het botverlies van postmenopausale vrouwen met subklinische hyper-
thyreoïdie en multinodulair struma afgeremd kan worden door thyreostatische
behandeling met methimazol, terwijl het botverlies doorgaat als de subklinische
hyperthyreoïdie niet wordt behandeld.
De onderzoeken beschreven in dit proefschrift tonen aan dat "subklinische"
hyperthyreoïdie niet wezenlijk verschilt van "manifeste" hyperthyreoïdie en als
zodanig behandeld zou moeten worden.
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NAWOORD
Het onderzoek beschreven in dit proefschrift werd uitgevoerd in het Slingeland
Ziekenhuis te Doetinchem. De patiënten en vele vrijwilligsters die bereid waren
deel te nemen aan dit onderzoek ben ik zeer erkentelijk.
Met grote waardering voor zijn vele opvallende kwaliteiten wil ik Professor
dr. A.C. Nieuwenhuijzen Kruseman bedanken. Door zijn enthousiasmerende
begeleiding heb ik aan dit onderzoek veel vreugde beleefd en heeft niet de zo
gevreesde "promotie-onderzoeks-ontgoocheling" toegeslagen. Door zijn
scherp-analytisch vermogen, efficiënte werkwijze en zijn stuurmanskunst de
hoofdlijn consequent te blijven volgen, is de tijdsbesteding in hoge mate effec-
tief geweest, zodat het mogelijk was dit proefschrift te volbrengen naast een
praktijk als internist zonder dat het aantal uren slaap beneden een kritisch
minimum daalde.
Dr. F.J.L. Reijnders stond mij letterlijk als een "auctor intellectualis" bij ter
plaatse van het onderzoek, in Doetinchem. Zeer erkentelijk ben ik hem voor de
stimulerende discussies en zijn daadwerkelijke hulp bij de uitvoering van het
onderzoek. Zijn nauwgezetheid was van een grotere orde dan ik tevoren had
vermoed. Zijn kritisch oordeel getuigde ervan dat hij zich, als gynaecoloog
goeddeels onbekend met de materie, serieus in het onderwerp heeft verdiept.
Mijn collega H. Drost ben ik zeer erkentelijk voor zijn aandeel in de uitvoe-
ring van het onderzoek naar de cardiale invloed van subklinische hyperthyreo-
ïdie en zijn relativerende, nuchtere kritiek.
Het personeel van de Interne functie-afdeling van het Slingeland Ziekenhuis
te Doetinchem verrichtte zonder enig eigenbelang de vele botdensitometrieèn.
Els, Els, Rini, Riny, Anja, Karin, Lydia, Marlie en Annemie, ik ben jullie
hiervoor zeer erkentelijk.
H. Jonkers en A.J. Bastiaanse wil ik bedanken voor de vele biochemische
bepalingen die zij, mede met behulp van het personeel van het Isotopenlabora-
torium, hebben verricht.
Janny Schuurman-van Valburg en Letty Hendriks-Bouwmeester ben ik zeer
veel dank verschuldigd voor het typewerk, waarmee zij uiteindelijk na vele
versies tot op de komma's en punten nauwkeurig het werk hebben volbracht.
De direktie van het Slingeland Ziekenhuis te Doetinchem, ten tijde van het
onderzoek drs. Fr.C.A. Jaspers en dr. L. Weeda, ben ik erkentelijk voor de
geboden faciliteiten.
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Dr. A.P.M. van Oudheusden ben ik zeer erkentelijk voor zijn kritische
opmerkingen en het geboden onderdak in Rekem.
Tenslotte wil ik Ada Mudde-Groot, mijn echtgenote, bedanken, voor haar
non-oppressieve steun; omdat het niet hoefde en omdat het toch kon.
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